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Management of canine hypoadrenocorticism relies on supplementation of 
glucocorticoids and mineralocorticoids. Although previous studies show success of both 
a steroid with combined activity (fludrocortisone) and steroids with separate activities 
(DOCP with prednisolone) in the management of canine hypoadrenocorticism, the two 
treatment methods had never been prospectively compared. 
The objective of this clinical trial was to compare fludrocortisone to DOCP with 
prednisolone for the management of canine hypoadrenocorticism in stable patients. 
A prospective, randomised, cross-over, non-blinded, non-inferiority trial was conducted. 
Patients were randomised into two groups: Group A received three months of treatment 
with the interventional product (DOCP and prednisolone) followed by three months of 
the control product (fludrocortisone) whilst Group B received three months of the 
control product followed by three months of the interventional product. Primary 
outcome measures were electrolyte concentrations and clinical signs at the end of each 
phase of the trial. Secondary outcome measures included plasma renin activity, 
endogenous ACTH, blood pressure and routine haematology/biochemistry results.  
No dogs had clinical signs of hypoadrenocorticism or hyponatraemia/hyperkalaemia at 
the end of the DOCP phase of the trial. Three dogs however were hyponatraemic at the 
end of the fludrocortisone phase of the trial, although no patients were hyperkalaemic or 
showed clinical signs of hypoadrenocorticism.  The blood pressure was significantly 
higher (Paired T test; P=0.006) at the end of the DOCP phase (mean 161mmHg; SD 
26.3) than at the end of the fludrocortisone phase (mean 147mmHg; SD 26.2). The 
neutrophil count was significantly higher (Paired T test; P=0.009) at the end of the 
DOCP phase (mean 7.49x10^9/L; SD 3.1) compared to the fludrocortisone phase (mean 
5.81x10^9/L; SD 2.31). The urea was significantly lower (Wilcoxon Signed Rank test; 
P <0.001) at the end of the DOCP phase (median 5.3mmol/L; 2.9-11.7) compared to the 
end of the fludrocortisone phase (median 7.4mmol/L; 3.8-17.2). The creatinine was also 
significantly lower (Paired T test; P=0.001) at the end of the DOCP phase (mean 
96umol/L; 19.2) compared to the fludrocortisone phase (mean 109umol/L 28.9). The 
ACTH and renin concentrations were significantly lower at the end of the DOCP phase 
compared to the fludrocortisone phase (Wilcoxon Signed Rank test; both P <0.001). 
In conclusion, DOCP with prednisolone appears to be non-inferior to fludrocortisone 
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1 Introduction: Review of the literature on canine 
hypoadrenocorticism and its management  
1.1 The Adrenal Gland 
1.1.1 The Anatomy of the Adrenal Gland 
The adrenal gland is a yellow-white organ situated medial to both kidneys, lateral to the 
renal vessels and dorsal to the vena cava. They are flattened dorsoventrally and in dogs 
the normal gland is around 2-3cm long and 1cm wide (Singh and Dyce, 2018). Adrenal 
gland size is not necessarily correlated with body weight or breed in dogs 
(Juodžiukynienė et al., 2014). The adrenal gland can be separated into distinct regions 
both histologically and functionally. Anatomically, the adrenal gland consists of an 
inner medulla and an outer cortex. The cortex can then be separated into 3 layers: the 
outer zona glomerulosa (25%) which comprises columns of cells in a sigmoid 
arrangement; the middle zona fasciculata (60%) which contains cells with cytoplasm 
abundant in lipid and are surrounded by numerous small capillaries (Rosol and Grone, 
2016) and the inner zona reticularis (15%) which contains numerous secretory cells 
surrounded by capillaries (Van Lanen and Sande, 2014).  Ultrasonographically, the 
adrenal glands are located cranial and medial to each kidney, with the 
phrenicoabdominal vein running ventral to the gland and the phrenicoabdominal artery 
coursing dorsally. Normal adrenal glands are contained within a small hyperechoic 
capsule with a hypoechoic, homogenous centre (Barthez et al., 1998). The right adrenal 
gland is more difficult to locate given its more cranial position. Left adrenal gland 
thickness <3.2mm is highly suggestive of hypoadrenocorticism (Wenger et al., 2010). 
1.1.2 The Physiology of the Adrenal Gland 
The main role of the adrenal gland is to produce hormones. The adrenal medulla 
produces catecholamines whilst the adrenal cortex produces glucocorticoids, 
mineralocorticoids and androgens (Cunningham and Klein, 2013). In 
hypoadrenocorticism, the hormones of most significance are cortisol and aldosterone.  
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1.1.2.1 Cortisol Production and Action 
Production of cortisol (a glucocorticoid) from cholesterol is complex, involving 
numerous enzymes and is reviewed elsewhere (Auchus and Miller, 2016). Control of 
glucocorticoid release is regulated by the hypothalamic-pituitary axis (HPA). 
Corticotrophin (CRH) is released from the hypothalamus and activates receptors on the 
anterior pituitary gland, stimulating the release of adrenocorticotrophic hormone 
(ACTH). This hormone then travels via the blood to the adrenal cortex where it 
stimulates cortisol production and secretion from the zona fasciculata and reticularis. 
Cortisol has a negative feedback effect on both CRH and ACTH release, therefore self-
regulating its control. In other species such as humans, ACTH concentrations fluctuate 
with circadian rhythm. This is not the case in dogs however ACTH can be stimulated by 
arginine vasopressin (AGP), angiotensin II, cholecystokinin (CCK), atrial natriuretic 
factor (ANP) and vasoactive peptides, irrespective of cortisol concentrations. In 
addition, ACTH concentrations can be affected by stress and hypoglycaemia, secondary 
to their stimulation of CRH release (Scott-Moncrieff, 2015). 
Glucocorticoids have a vast number of actions and they are an important mediator of 
physiological stress. Glucocorticoids also stimulate gluconeogenesis and glycolysis as 
well as protein and fat catabolism. They maintain intestinal cell integrity and are 
important in digestion and absorption within the gastrointestinal tract (Langlais-Burgess 
et al., 1995). Although cortisol does bind (with as much infinity) to mineralocorticoid 
receptors, it does not have as potent mineralocorticoid effects as it is readily de-
activated to cortisone in the collecting ducts where these receptors are found (Scott-
Moncrieff, 2015).  
1.1.2.2 Aldosterone Production and Action 
The zona glomerulosa is the only layer of the adrenal cortex which is capable of 
secreting aldosterone. This is because it is the only region containing the enzyme 
aldosterone synthase (P450 c11AS) which is required for its synthesis. In addition, the 
zona glomerulosa does not contain 17-alpha-hydroxylase (P450 c17) and therefore, 
cannot synthesise cortisol (Scott-Moncrieff, 2015).  
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The secretion of aldosterone is stimulated by angiotensin II and increased plasma 
potassium concentrations (and to a lesser extent, decreased sodium concentrations). 
Aldosterone causes upregulation of the sodium/potassium ATPase pump in the distal 
convoluted tubule of the kidney, which results in reabsorption of sodium and excretion 
of potassium. As water moves with sodium, this results in increasing the circulating 
plasma volume and therefore, blood pressure. Chloride is also absorbed via the 
paracellular pathway and sodium can be absorbed by the collecting tubule cells in 
exchange for hydrogen ions (Cunningham and Klein, 2013). This regulation of blood 
pressure is controlled by the renin-angiotensin-aldosterone system. Renin is released 
from the macula densa of the juxtaglomerular apparatus of the kidneys (at their 
glomeruli) in response to reduced sodium concentrations or extracellular fluid volume. 
This results in the conversion of angiotensin to angiotensin I in the liver. Angiotensin I 
is then converted to angiotensin II in the lungs, before stimulating aldosterone release 
from the zona glomerulosa. The increased sodium concentrations achieved following 
aldosterone release result in reduced release of renin. When ACTH is completely 
absent, reduction in aldosterone secretion is seen, however complete hypophysectomy 
does not result in low aldosterone concentrations(Rauschkolb et al., 1956). Therefore, 
ACTH is thought to have a minimal effect on aldosterone release.  
1.2 Causes of hypoadrenocorticism  
1.2.1 Primary Hypoadrenocorticism 
Primary hypoadrenocorticism is caused by bilateral destruction of the adrenal cortices. 
Clinical signs develop once 90% or more of the relevant adrenal cortex zona is non-
functional (Boag et al., 2015, Bellumori et al., 2013, Boujon et al., 1994). In over 95% 
of dogs, the condition is idiopathic and suspected to be due to immune mediated 
destruction of the gland. Histologically affected glands have lymphocytic infiltrate 
(Boujon et al., 1994) with a lesser population of plasma cells and macrophages. The 
predominant population is CD 4+ T cells and there is also histological evidence of 
replacement of the glandular tissue with fibrous tissue in the later stages of the disease, 
as the glands atrophy (Friedenberg et al., 2016).  In humans, this autoimmune disease is 
caused by circulating autoantibodies against 21-hydroxylase11 and p450 side chain 
cleavage and more recently this has been demonstrated in some dogs (Boag et al., 2015, 
Boag and Catchpole, 2014).  
INTRODUCTION 
13 
In classical primary hypoadrenocorticism, destruction of the zona glomerulosa and 
fasciculata are seen, resulting in both mineralocorticoid and glucocorticoid deficiency. 
However, “atypical hypoadrenocorticism” describes a subset of patients who present 
with glucocorticoid deficiency only (Sadek and Schaer, 1996, Thompson et al., 2007). 
These patients have only destruction of their zona fasciculata.  
There are many clinical manifestations of glucocorticoid deficiency. These include 
hypoglycaemia due to reduced gluconeogenesis and glycogenolysis and reduced protein 
and fat metabolism, resulting in weakness, weight loss and muscle wastage (Peterson et 
al., 1996). Patients with glucocorticoid deficiency also have a reduced ability to cope 
with physiological stress or infectious stimuli. Without the effects on gastrointestinal 
cell and brush border regeneration, diarrhoea can be seen however other gastrointestinal 
signs such as vomiting and inappetence can also be seen and this is thought to be multi-
factorial. Causes of gastrointestinal signs include reduced peristalsis, poor intestinal 
absorption, hypovolaemia, poor perfusion and vascular stasis. These effects in turn can 
cause gastrointestinal ulceration and blood loss (Thompson et al., 2007).  
Deficiency of aldosterone leads to hypovolaemia and clinically, to dehydration. It can 
also lead to hyperkalaemia which results in bradycardia and conduction abnormalities of 
the heart. With aldosterone deficiency, a mild metabolic acidosis can also be seen given 




Numerous other causes of adrenal gland atrophy (primary hypoadrenocorticism) have 
been reported. Neoplastic causes can be primary neoplasia such as lymphoma or 
metastatic neoplasia (Buckley et al., 2017). Other than lymphoma, it is not common for 
primary tumours to affect both glands (Kook et al., 2010) and therefore metastatic 
neoplasia is more common, with 21% of disseminated metastasis affecting these glands 
(Scott-Moncrieff, 2015). The most common tumours to metastasise to an adrenal gland 
include pulmonary, mammary, prostatic and pancreatic carcinomas (Labelle and De 
Cock, 2005). Infectious causes include fungal conditions (including blastomycosis, 
histoplasmosis and cryptococcosis) which cause granulomatous destruction of the 
adrenal gland (Scott-Moncrieff, 2015). The most common cause of primary 
hypoadrenocorticism, other than idiopathic destruction of the gland, is iatrogenic 
destruction caused by drugs such as trilostane and mitotane which are used in the 
management of hyperadrenocorticism (Reusch et al., 2007, Vilar and Tullner, 1959, 
Reid et al., 2014, Ramsey et al., 2008). Sporadic reports of primary 
hypoadrenocorticism include a report of 6 Beagles exposed to aerosols of plutonium-
238 (Weller et al., 1996). 
1.2.1.1 Signalment   
Several breeds are thought to be over represented in populations of dogs with primary 
hypoadrenocorticism (Summers et al., 2010, Bellumori et al., 2013). In addition, several 
breeds have been recognised as being genetically predisposed including: Portuguese 
Water Dogs (Chase et al., 2006, Oberbauer et al., 2006); Nova Scotia Duck Tolling 
Retriever (Burton et al., 1997, Hughes et al., 2010, Hughes et al., 2007, Hughes et al., 
2011); Standard Poodle (Shaker et al., 1988, Famula et al., 2003, Friedenberg et al., 
2017); and Bearded Collie (Oberbauer et al., 2002). The condition has autosomal 
recessive heritability in the former three breeds but the heritability is unclear in the 
Bearded Collie (Scott-Moncrieff, 2015). In these breeds, several genes have been 
associated with increased susceptibility to hypoadrenocorticism. Some of these genes 
overlap with those found in humans with hypoadrenocorticism. Despite considerable 
research, the genetics of the susceptibility to hypoadrenocorticism is still poorly 
understood and no genetic or serological tests are currently available. Although no large 
scale genetic studies have been carried out, there is also anecdotal evidence for 
increased incidence of the condition in Soft Coated Wheaten Terriers (Haviland et al., 
2016), West Highland White Terriers, Great Danes and Cocker Spaniels (Short et al., 
2014, Short et al., 2013). It is suspected that there are variations and overlap between 
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the mechanism of autoimmunity between breeds and perhaps between individual 
patients (Boag and Catchpole, 2014). 
Although patients can present with hypoadrenocorticism at any age (range 4 weeks to 
16 years), they are usually young to middle aged with a median age of 4 to 5 years 
(Klein and Peterson, 2010a, Kintzer and Peterson, 1997a). Female dogs are over-
represented at 69% of the total dog population (Hanson et al., 2016). There are however 
breed variations, for example, Nova Scotia Duck Tolling Retrievers present at a younger 
median age of 2.6 years and in this breed, Bearded Collies and Poodle breeds, there 
appears to be equal sex distribution (Oberbauer et al., 2006, Oberbauer et al., 2002, 
Famula et al., 2003).  In addition, it has been suggested that neutered dogs are three 
times more likely to develop the condition compared to entire dogs (Kelch et al., 1998).  
1.2.2 Secondary Hypoadrenocorticism 
Spontaneous secondary or tertiary hypoadrenocorticism is rare. It is caused by reduction 
in ACTH or CRH from the hypothalamus and pituitary gland respectively. This has 
been reported in humans due to neoplasia or traumatic lesions, however this has not 
been reported in the dog. The only known cause of spontaneous secondary 
hypoadrenocorticism in the dog is pituitary apoplexy which can result in neurological 
signs and adrenal crisis (Bertolini et al., 2007).  More commonly, secondary 
hypoadrenocorticism is caused by sudden withdrawal of glucocorticoids following long 
term use at doses higher than the physiological dose. This chronic glucocorticoid 
therapy causes reduced necessity for ACTH release from the pituitary gland and 
therefore transient anterior pituitary and adrenal gland atrophy can occur (Pey et al., 
2012).  ACTH suppression can occur any time from a few days after initiation of steroid 
therapy, however individual response to exogenous corticosteroids is variable (Scott-
Moncrieff, 2015). Less commonly, iatrogenic secondary hypoadrenocorticism can be 
caused by hypophysectomy for management of pituitary dependant 
hyperadrenocorticism (Hanson et al., 2005) or medical management of pituitary or 
adrenal dependant hyperadrenocorticism (den Hertog et al., 1999, Alenza et al., 2006, 




1.3 Investigation of hypoadrenocorticism  
1.3.1 Historical and clinical examination findings in dogs with 
hypoadrenocorticism 
1.3.1.1 History and Clinical signs  
Hypoadrenocorticism is an uncommon condition with a prevalence of 0.06-0.28% in 
one referral hospital population in the United States of America (Kelch et al., 1998). 
Patients present with variable signs and urgency to clinicians. Clinical signs are vague 
with the most common being lethargy (67-76%), followed by anorexia (52-73%), 
vomiting (62-68%) and diarrhoea (29-56%) (Haviland et al., 2016, Wakayama et al., 
2017). Less common clinical signs include polyuria/polydipsia (8%), weight loss (8%), 
generalised weakness (3%) and gait abnormalities (2%) (Haviland et al., 2016). Rare 
clinical signs have been reported such as regurgitation (Whitley, 1995), muscle cramps 
(Saito et al., 2002) and seizures (Van Lanen and Sande, 2014). The history of these 
signs can range from days to years, depending on the rate of adrenal gland atrophy and 
the patient’s ability to compensate (Scott-Moncrieff, 2015). Generally, but not always, 
dogs with atypical hypoadrenocorticism tend to have a more insidious onset of disease 
(Wakayama et al., 2017). Often patients have waxing and waning signs or disease that is 
the sequel to a stressful event (Scott-Moncrieff, 2015). They may also have a history of 
re-occurring signs which respond to symptomatic therapy such as with fluid therapy 
(Scott-Moncrieff, 2015).  
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1.3.1.2 Physical examination findings 
As with historical findings, physical examination findings are vague and some patients 
may have no abnormalities on physical examination. Findings can be attributed to the 
underlying glucocorticoid or mineralocorticoid deficiencies. One of the most common 
clinical findings is dehydration, which is due to the inability to conserve sodium in the 
distal convoluted tubules and collecting ducts of the kidneys (Scott-Moncrieff, 2015, 
Van Lanen and Sande, 2014). This hypovolaemia results in a reduction in blood 
pressure, with median systolic blood pressures being reported to be low at 90mmHg 
(Seth et al., 2011). Clinically dehydrated patients that do not have hypoadrenocorticism 
normally present with compensatory tachycardia and therefore, dehydrated patients with 
a normal or low heart rate (or even bradycardia) should prompt consideration of 
hypoadrenocorticism (Van Lanen and Sande, 2014). In these patients, the bradycardia is 
secondary to hyperkalaemia which results from the inability to excrete potassium from 
the kidneys. This change can also result in arrhythmias or muscle cramping (Saito et al., 
2002).  
Another common clinical finding is muscle wastage which is due to an inability to 
metabolise and utilise energy adequately and this can also result in weakness (Hughes et 
al., 2007). Patients can occasionally develop melaena or haematochezia due to poor 
enterocyte regeneration and ischaemic injury due to hypovolaemia. This can lead to 
anaemia which results in pale mucous membranes on examination (Scott-Moncrieff, 
2015).  
Given the vague findings on history and physical examination, there are numerous 
differential diagnoses for hypoadrenocorticism. These include gastrointestinal disease 
(such as inflammatory bowel disease), renal disease, hepatic disease and other 
endocrinopathies such as diabetic ketoacidosis. It is not uncommon for patients to have 
exploratory laparotomies performed to assess for obstructed foreign material within the 
gastrointestinal tract. Therefore routine investigations are required to exclude other 
causes of the vague signs and to increase the clinical suspicion of this condition, before 
performing confirmatory testing.  
Historical and physical examination findings are discussed in more detail in other 
sources (Spence et al., 2018, Ettinger et al., 2017, Scott-Moncrieff, 2015, Mooney and 
Peterson, 2012, Hess, 2018, Church, 2012). 
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1.3.2 Clinical pathological changes associated with hypoadrenocorticism  
1.3.2.1 Haematology 
The most common haematological abnormality seen with hypoadrenocorticism is the 
absence of a stress leukogram in a sick patient. A reverse stress leukogram is 
represented by low neutrophils with a lymphocytosis and eosinophilia. Only 10 to 30% 
of patients with hypoadrenocorticism have a reverse stress leukogram, however over 
90% has lack of a stress leukogram (Hess, 2018). In normal circumstances, cortisol 
causes lymphocytes to remain in the bone marrow and lymph nodes instead of being 
released, due to sequestration. In hypoadrenocorticism, the lack of cortisol prevents this 
from happening and therefore circulating lymphocytes increase (Scott-Moncrieff, 
2015). Lymphocyte counts have been used to assist the diagnosis of 
hypoadrenocorticism with lymphocyte counts <0.75x10^3/µL excluding the condition 
(Seth et al., 2011). Neutropenia is less commonly seen than lymphocytosis and most 
commonly neutrophils are in the normal reference range. This is an uncommon finding 
in sick patients and up to 32% of patients with hypoadrenocorticism can have a 
neutrophilia (Hess, 2018). Eosinophilia is seen more commonly than lymphocytosis 
(20%) but a high eosinophil count is not as sensitive for detecting the condition 
(Chastain et al., 1989, Seth et al., 2011). 
Another common haematological finding is a normocytic, normochromic, non-
regenerative anaemia. This is primarily due to a lack of red blood cell production in the 
bone marrow due to cortisol deficiency, however it can also be in part due to 
gastrointestinal blood loss. Up to 15% of dogs are thought to have melaena and this can 
result in severe anaemia (Scott-Moncrieff, 2015). Often the anaemia can be masked by 
severe dehydration at the time of presentation, not becoming apparent until fluid 
resuscitation has been commenced. Generally, the anaemia is more marked with 
patients affected by atypical hypoadrenocorticism as the condition is not diagnosed as 




The clinicopathological finding most classically associated with hypoadrenocorticism is 
a derangement in electrolyte concentrations. Hyperkalaemia is the most common 
change, followed by hyponatraemia (Peterson et al., 1996). Given the high occurrence 
of the alterations in sodium and potassium, the sodium and potassium ratio has 
historically been used to increase the clinical suspicion of hypoadrenocorticism. The 
normal sodium:potassium ratio ranges from 27:1 to 40:1 and lower ratios are thought to 
be more specific for cases of hypoadrenocorticism (Bartges and Nielson, 1992). A ratio 
of 24:1 has been suggested as a cut-off concentration for diagnosis of this condition, 
with a specificity of 100% (Adler et al., 2007). However, evidence for the use of 
sodium:potassium ratios in the diagnosis of hypoadrenocorticism is contradictory, with 
numerous other conditions resulting in hyperkalaemia and hyponatraemia (Adler et al., 
2007, Nielsen et al., 2008, Roth and Tyler, 1999, Scott-Moncrieff, 2015, Schaer et al., 
2001).  
Conversely, some dogs with hypoadrenocorticism have normal electrolyte 
concentrations including dogs with atypical hypoadrenocorticism, as mineralocorticoid 
deficiency preventing renal electrolyte exchange is not a feature. Not all dogs with 
normal electrolytes have the atypical form of the disease however with some patients 
with hypoadrenocorticism demonstrating compensation for the aldosterone deficiency 
(Baumstark et al., 2014b). Either hyperkalaemia or hyponatraemia are more commonly 
associated with hypoadrenocorticism than changes in both electrolytes and up to 30% of 
patients have electrolyte concentrations completely within the normal range (Hughes et 
al., 2007). Therefore, it is currently considered important to measure aldosterone in 
patients with normal electrolytes, to distinguish between classical and atypical 
hypoadrenocorticism, however further research is needed in this area.   
Other electrolyte abnormalities seen include hyperphosphataemia (68%), 
hypochloraemia (42%) and hypercalcaemia (32%) (Hess, 2018). These changes are 
probably due to altered electrolyte exchange within the kidneys due to 
mineralocorticoid deficiency (chloride) and glucocorticoid deficiency 




Almost 90% of patients with hypoadrenocorticism are azotaemic which reflects the lack 
of reabsorption of water from the kidneys, hypotension and reduced renal perfusion. 
This can be marked and can be difficult to distinguish from an acute kidney injury 
(Peterson et al., 1996). Clinically, in hypoadrenocorticism there is often a quick 
resolution of the azotaemia with fluid therapy, however this is not the case with an acute 
kidney injury. Sometimes the increase in urea is proportionally more marked than the 
increase in creatinine. This can be in part due to gastrointestinal bleeding resulting in an 
increase in urea (Scott-Moncrieff, 2015). 
Hypoglycaemia can occur in up to 30% of patients and in some cases can be severe 
enough to cause seizures (Lifton et al., 1996), particularly in dogs with atypical disease. 
This is because glucocorticoid deficiency causes reduced gluconeogenesis and 
peripheral sensitivity to insulin (Scott-Moncrieff, 2015). Another finding seen more 
commonly in dogs with atypical disease, but in all forms of hypoadrenocorticism, is 
hypoalbuminaemia (6-39%) and hypocholesterolaemia (7%). These changes are thought 
to be due to hepatic dysfunction (both albumin and cholesterol), protein losing 
enteropathy (albumin) and alterations in fat metabolism (cholesterol) (Scott-Moncrieff, 
2015). As these patients often have increases in liver enzymes (30%), liver disease and 
hypoadrenocorticism can mimic each other both in terms of clinical signs and 
clinicopathological findings.  
Finally, mineralocorticoid deficiency can result in a mild metabolic acidosis, due to 
impaired hydrogen ion excretion. It can also be due to hypovolaemia resulting in poor 
tissue perfusion and lactic acidosis (Kintzer and Peterson, 1997b). 
1.3.2.4 Urinalysis 
Although patients with hypoadrenocorticism are clinically dehydrated, they are unable 
to conserve water, and this results in a USG <1.030. Therefore, hypoadrenocorticism 
should be considered in dehydrated patients with a USG less than 1.030.  
1.3.2.5 Imaging 
Radiography, abdominal ultrasound and echocardiography are all useful in excluding 
differential diagnoses and significant co-morbidities or complications (Van Lanen and 
Sande, 2014, Whitley, 1995, Feldman and Peterson, 1984, Peterson et al., 1996, Melian 




1.4 Confirming the diagnosis of hypoadrenocorticism  
1.4.1 Basal cortisol 
A basal cortisol >55nmol/L has a sensitivity of 100% for the exclusion of 
hypoadrenocorticism (Bovens et al., 2014). This is more sensitive than the cut-off of 28 
nmol/L which was previously used, which has a sensitivity of only 85.7% (Bovens et 
al., 2014, Lennon et al., 2007). Although basal cortisol is an excellent exclusion test, it 
cannot be used for diagnosis of hypoadrenocorticism. Basal cortisol concentrations <22 
nmol/L have a specificity of 95.7-98.2% and when <55 nmol/L, a specificity of only 
78% (Lennon et al., 2007, Gold et al., 2016).  Cortisol concentrations <5.5nmol/L had a 
specificity of 99.1% (Gold et al., 2016), however it should be noted that the accuracy 
and precision of many cortisol assays at this concentration has not been tested.  
Cortisol is stable in serum and urine at 4oC and 25oC for 5 days (Behrend et al., 1998). 
It is measured in plasma or serum by radioimmunoassay, chemiluminescent assay or 
enzyme-linked immunosorbent assay (Russell et al., 2007).  
1.4.2 ACTH stimulation test 
The standard diagnostic test for the diagnosis of hypoadrenocorticism is the ACTH 
stimulation test. The use and potential confounding factors of this test have been 




This test involves obtaining a serum sample for measurement of basal cortisol, then 
giving synthetic ACTH intravenously or intramuscularly and then taking a second 
serum sample for cortisol measurement 30 to 90 minutes later. A depot intramuscular 
injection with a longer acting formulation of ACTH containing inorganic zinc 
complexes has also been shown to be effective in the diagnosis of hypoadrenocorticism 
(Sieber-Ruckstuhl et al., 2015). The lowest dose of ACTH found to stimulate the 
adrenal gland is 0.5µg/kg (Martin et al., 2007) and the lowest dose found to cause 
maximal stimulation of the adrenal gland in patients suspected to have 
hypoadrenocorticism is 5 µg/kg (Lathan et al., 2008).  There is no benefit of using 
higher doses of ACTH (such as 250µg/dog) and therefore 5 µg/kg has become the 
recommended dose (Lathan et al., 2008). No differences have been shown in peak 
cortisol concentration when comparing intravenously and intramuscularly administered 
ACTH (Cohen and Feldman, 2012). In addition, perivascular administration of synthetic 
ACTH has not been shown to affect ACTH stimulation test results in dogs with 
hyperadrenocorticism and therefore subcutaneous administration should not affect 
results of the ACTH stimulation test (Johnson et al., 2017). Most protocols suggest that 
post ACTH serum samples are collected at 60 minutes, however sampling time ranges 
from 30 to 90 minutes (Frank et al., 2000). Dogs do not exhibit circadian rhythm of 
cortisol release and therefore time of day is not an important factor in sampling (Scott-
Moncrieff, 2015). 
 Diagnosis of hypoadrenocorticism is made when pre and post ACTH concentrations 
are <55 nmol/L and this has a sensitivity and specificity of 100% in diagnosing 
hypoadrenocorticism (in the absence of exogenous glucocorticoid administration). It 
does however not distinguish between dogs with spontaneous hypoadrenocorticism and 
those on exogenous glucocorticoid therapy. Most dogs with this condition have cortisol 
concentrations under 28 nmol/L before and after synthetic ACTH administration (Scott-
Moncrieff, 2015).  
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1.4.3 Plasma ACTH concentrations 
Plasma ACTH concentrations are increased in dogs with primary hypoadrenocorticism 
(Boretti et al., 2015) due to a lack of negative feedback of cortisol on the HPA axis. 
Plasma ACTH concentrations are also increased in patients with pituitary dependant 
hyperadrenocorticism, however the clinical presentation and ACTH stimulation test 
results would be very different between these two conditions (Scott-Moncrieff, 2015). 
ACTH to cortisol ratios (CAR) have been proposed as a promising screening test, 
however further studies are required (Boretti et al., 2015, Javadi et al., 2006, Lathan et 
al., 2014). 
Plasma ACTH can be measured by a radioimmunoassay or a chemiluminescent assay, 
both of which have been validated in dogs (Scott-Moncrieff et al., 2003). Sample 
handling is very important and blood samples must be obtained in EDTA anti-
coagulated blood and separated within 15 minutes of collection. Finally, the sample 
must be frozen immediately after separation (Scott-Moncrieff, 2015) and the sample 
should also not be in contact with glass at any point as ACTH adheres to glass, causing 
falsely low results. 
1.4.4 Plasma aldosterone concentrations  
In dogs with primary hypoadrenocorticism, plasma aldosterone tends to be below lower 
reference limits, however there is overlap between these patients and healthy dogs 
(Baumstark et al., 2014b). Many studies have looked at plasma aldosterone following 
ACTH stimulation however ACTH has only a minimal effect on plasma aldosterone at 
physiological levels. In patients with atypical hypoadrenocorticism, where there is 
glucocorticoid deficiency only, the plasma aldosterone concentrations are within the 
normal range (Thompson et al., 2007, Lifton et al., 1996). 
Plasma aldosterone is measured by a radioimmunoassay (Sieber-Ruckstuhl et al., 2006). 
The test is run on serum samples and as with cortisol, plasma aldosterone is relatively 
stable. Samples can be stored for 7 days between 2C and 8C and for up to two months at 
temperatures less than -20C (Scott-Moncrieff, 2015). 
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1.4.5 Plasma renin activity  
When aldosterone is low, plasma renin activity increases (Montori and Young, 2002). 
Therefore, dogs with classical primary hypoadrenocorticism have an increase in plasma 
renin activity (Baumstark et al., 2014a). Plasma renin activity is measured using an 
angiotensin radioimmunoassay (Boer et al., 1985). As with plasma ACTH 
measurement, samples should be obtained in EDTA anti-coagulated blood and 
separated within 15 minutes of collection before freezing. 
1.4.6 Aldosterone-to-renin ratio 
With both plasma aldosterone and plasma renin activity, there can be overlap between 
healthy dogs and dogs with hypoadrenocorticism. The aldosterone to renin ratio is a 
much more sensitive test of mineralocorticoid deficiency and classical 




1.5 Treatment of hypoadrenocorticism  
Treatment of hypoadrenocorticism is largely dependent on whether patients present as 
an emergency in an acute adrenal crisis or whether they have more chronic, less severe 
signs. Treatment also depends on whether a diagnosis has been made, as many 
treatments can interfere with diagnostic confirmation of the condition as discussed 
(Spence et al., 2018).  
1.5.1 Acute management 
1.5.1.1 Intravenous fluid therapy 
Most patients who present acutely have a severe mineralocorticoid deficiency, resulting 
in dehydration, hypovolaemia and hypotension, often with concurrent electrolyte 
disturbances. Therefore, aggressive fluid therapy is the mainstay of treatment in the 
acute setting, and appropriate fluid therapy can alleviate all signs in the short term, 
whilst awaiting results of diagnostic testing.  
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Crystalloid fluid therapy is the most appropriate choice and more specifically, 0.9% 
sodium chloride provides the most rapid correction of the hyponatraemia and 
hypokalaemia. It is however less effective compared to compound sodium lactate at 
resolving metabolic acidosis when present. When patients have a marked 
hyponatraemia (<120mmol/L), 0.9% sodium chloride should be avoided as rapid 
correction of hyponatraemia can lead to delayed pontine osmotic demyelination 
(O'Brien et al., 1994, Churcher et al., 1999). This results in delayed and severe 
neurological deficits and is associated with correction of sodium at rates quicker than 
10-12mmol/L per day of 0.5mmol/L per hour (Churcher et al., 1999). If there are 
concerns over marked hyponatraemia or rapid increase in sodium concentrations then 
compound sodium lactate would be the preferred choice of fluid. Colloid fluid therapy 
is rarely required unless there is a marked hypoalbuminaemia which could be 
exacerbated by aggressive fluid therapy (Scott-Moncrieff, 2015).  
An adrenal crisis is one of the few situations where true shock rates of intravenous fluid 
therapy are required. This can be achieved by giving repeated boluses of 10 to 20 ml/kg 
over 15 minutes with frequent reassessment during this period to address the patient’s 
response and requirement for on going aggressive fluid therapy. Often rates of 40 to 
80ml/kg are required over the first two hours (Gunn et al., 2016). 
1.5.1.2 Management of electrolyte disturbances 
In most patients, initiation of fluid therapy rapidly corrects electrolyte disturbances or at 
least reduces potassium concentrations from dangerous to safe concentrations. If 
hyperkalaemia does not resolve within the first 15 minutes of treatment, if there is a 
persistently marked hyperkalaemia of >7.0mmol/L or if there is a severe bradycardia, 
then treatment can be considered (Scott-Moncrieff, 2015). Intravenous boluses of 10% 
calcium lactate (0.5ml/kg) diluted and given over twenty minutes will not reduce the 
potassium concentrations but will be cardioprotective (DiBartola, 2001), increasing the 
heart rate whilst the plasma serum potassium concentrations reduce with on going fluid 
therapy (Scott-Moncrieff, 2015). If potassium concentrations do not decrease with fluid 
therapy, then insulin (0.2 IU/kg) and glucose (1 – 2g/unit of insulin) can be 
administered (Scott-Moncrieff, 2015).  This therapy drives insulin intracellularly 
however potassium, glucose and phosphate (which is also driven intracellularly) should 
all be monitored closely.  
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1.5.1.3 Acute glucocorticoid and mineralocorticoid supplementation  
Ideally an ACTH stimulation test should be performed before giving any exogenous 
steroid preparation. If a patient is haemodynamically unstable before completion of an 
ACTH stimulation test, then dexamethasone is the steroid of choice to administer as it 
does not cross react with commercial cortisol assays. It can however affect the HPA 
axis by causing negative feedback to the pituitary gland, reducing ACTH release and 
therefore cortisol release. This means that the ACTH stimulation should be completed 
as soon after administering dexamethasone as possible (Kemppainen et al., 1989). It is 
important to note that dexamethasone is a pure glucocorticoid and will have no effect on 
mineralocorticoid deficiency. Hydrocortisone does however have equal 
mineralocorticoid and glucocorticoid effects and can be given as mineralocorticoid 
supplementation. As it does cross react with the cortisol assay, it should not be 
administered until post ACTH stimulation serum samples are obtained. Generally, 
steroid doses administered during adrenal crisis are variable but are most often 
increased to three to five times the physiological dose. This results in doses of 0.1 to 0.2 
mg/kg of dexamethasone intravenously or 5mg/kg of hydrocortisone sodium succinate 
intravenously (Scott-Moncrieff, 2015). It has also been shown that a constant rate 
infusion of hydrocortisone sodium succinate (0.5 – 0.625mg/kg/hour) results in a more 
rapid normalisation of electrolytes and clinical resolution of signs (Gunn et al., 2016). 
1.5.2 Chronic management 
Glucocorticoid supplementation is required in all dogs with hypoadrenocorticism, 
whether they have the classical or atypical form of the disease (Klein and Peterson, 
2010b, Spence et al., 2018). Mineralocorticoid supplementation is only required when 
there are electrolyte derangements or inappropriately low aldosterone (Baumstark et al., 
2014b, Wakayama et al., 2017).  
1.5.2.1 Prednisolone 
In stable patients, the most commonly used formulation for glucocorticoid 
supplementation is prednisolone tablets given once a day. Prednisolone is primarily a 
glucocorticoid and does not provide sufficient mineralocorticoid supplementation(Hess, 
2018). Side effects of this drug include polyphagia, polydipsia, polyuria, excessive 
panting and coat thinning (Plumb, 2018).  
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The starting dose of prednisolone is 0.1 – 0.22mg/kg/day, however a wide range of 
doses from <0.05mg/kg to 0.4mg/kg per day have been reported (Kintzer and Peterson, 
1997b). During times of physiological stress such as elective surgery or concurrent 
illness, glucocorticoid requirements may increase. Therefore, doses of glucocorticoid 
may need to be increased up to three to 5-fold (Klein and Peterson, 2010b).  
1.5.2.2 Fludrocortisone 
Fludrocortisone acetate is another formulation of steroid with both glucocorticoid and 
mineralocorticoid activity. Therefore, prednisolone is often not required as an 
adjunctive therapy long term. It has however been shown that the use of prednisolone in 
the initial management decreases the time until clinical stabilisation of the condition 
(Roberts et al., 2016). 
There are no licensed preparations of fludrocortisone for use in dogs. Early studies 
showed the range of fludrocortisone dose given subcutaneously in adrenalectomised 
dogs to be 0.38-3.6 µg/kg/day (Parlow et al., 1956).  The current starting dose is 0.02 
mg/kg/day, split over one or two doses (Plumb, 2018). The mean dose in stable patients 
is 0.01 to 0.08mg/kg/day orally (Scott-Moncrieff, 2015, Kintzer and Peterson, 1997b, 
Roberts et al., 2016). Although historically it was recommended to supplement this 
therapy with salt administration, this has not been shown to improve outcome (Kintzer 
and Peterson, 1997b). 
1.5.2.3 DOCP 
Desoxycorticosterone pivalate (DOCP) is a pure mineralocorticoid used in the chronic 
management of hypoadrenocorticism (McCabe et al., 1995, Lynn and Feldman, 1991, 
Lynn et al., 1993, Van Zyl and Hyman, 1994). As aldosterone can have a minimal effect 
on glucocorticoid receptors (Scott-Moncrieff, 2015), it is possible that it can result in 
very mild glucocorticoid activity. DOCP is a long-acting version of deoxycortisterone 
acetate (DOCA) which was initially formulated in the 1940’s and was investigated 
clinically in the 1950’s in adrenalectomised dogs (Baker et al., 1954). There was 
unequivocal evidence that a solubilised formulation of the drug was safer than a 
suspension which had resulted in a high rate of anaphylactic shock in rats. Of this 
solubilised formulation, the starting dose was found to be 125-250 µg/kg/day. 
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There are currently two microcrystalline licensed preparations available for use in dogs:  
Percorten® (Novartis) which is licensed in North America and Zycortal® (Dechra Ltd) 
which is licensed for use in dogs in Europe and North America. Both are available in a 
25mg/ml prolonged-release formulation and Zycortal® has been shown to be non-
inferior to Percorten® (Farr et al., 2020). DOCP has a rapid onset of action and therefore 
only a brief transition period of around 48 hours is required when transitioning from 
parenteral steroids (hydrocortisone) or fludrocortisone acetate (Scott-Moncrieff, 2015, 
Ramsey et al., 2016). 
The authorised starting dose of the currently used formulations of DOCP is 2.2mg/kg 
given subcutaneously (or intramuscularly in the case of Percorten®) every 25 – 28 days. 
Often a much lower dose is required for long term management, with the Percorten® 
dose range being 0.8 – 3.4mg/kg dose every 14 – 35 days (Kintzer and Peterson, 
1997b). Peak action of this drug is most common around day 10 (Jaffey et al., 2017). 
Side effects of overdose or under dose include hypotension and polydipsia (due to the 
hypernatraemia/hypokalaemia), depression, lethargy and gastrointestinal signs (Plumb, 
2018). Lower doses of 1.0mg/kg have been shown to provide effective 
mineralocorticoid supplementation in some dogs with no adverse effects (Bates et al., 
2013). However it is difficult to predict which dogs need more or less mineralocorticoid 
supplementation and therefore higher starting doses are required before tapering the 
drug to lower doses (Scott-Moncrieff, 2015). 
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Electrolyte concentrations 10-14 days following an injection reflect the peak activity of 
the drug and provide information on the drug dose used (Mason et al., 2017). 
Electrolyte concentrations at day 25-28 following injection provide information on the 
duration of action of the drug (Ettinger et al., 2017, Lynn et al., 1993, Hess, 2018).  The 
dosing interval has been extended in one study with a dosing frequency ranging from 
30-90 days with a 54-60% reduction in cost of treatment (Jaffey et al., 2017). In this 
study, 10% of dogs exhibited clinical signs of hypoadrenocorticism or electrolytes 
outwith the reference range. Extending the dosing interval did not result in an 
Addisonian crisis in any of these patients. DOCP is 90% bound to plasma proteins with 
only 10% free to exert a biological effect (Drugbank, 2019). This could result in 
prolonged duration of action of DOCP and is speculated to be the reason why individual 
dosing interval is variable between patients, however further studies are required (Jaffey 
et al., 2017) to investigate this. Marked variation has been noted between individuals 
since the earliest of studies (Baker et al., 1954) and it is for this reason that some 
clinicians believe that dosing intervals should not be extended as this can lead to an 
acute adrenal crisis. 
1.6 Monitoring of patients with hypoadrenocorticism 
1.6.1 Clinical signs 
Clinical signs are very important in assessing the clinical control of 
hypoadrenocorticism, regardless of which therapy patients are being treated with. It is 
particularly important in the case of assessing glucocorticoid supplementation, as there 
are no readily available, routine diagnostic tests available. As prednisolone and 
fludrocortisone both cross-react with cortisol assays (Krasowski et al., 2014) but do not 
give biologically equivalent results to endogenous cortisol, basal cortisol and ACTH 
stimulation tests serve no purpose following the initial diagnosis of 
hypoadrenocorticism. Although increases in alkaline phosphatase and a stress 
leukogram on haematology are often present with excessive steroid therapy (Moore et 
al., 1992), these are inaccurate markers of glucocorticoid supplementation. 
Monitoring glucocorticoid supplementation involves decreasing the prednisolone dose 
when clinical signs of steroid overdose are present (polyuria, polydipsia, polyphagia, 
excessive panting and coat thinning) and increasing the dose when patients show signs 
of glucocorticoid deficiency (lethargy and gastrointestinal signs) (Scott-Moncrieff, 
2015, Lathan and Thompson, 2018, Farr et al., 2020). Therefore, a thorough history is 
required at re-check visits.    
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Unfortunately, there can be some overlap between clinical signs of glucocorticoid 
excess, glucocorticoid deficiency, mineralocorticoid excess and mineralocorticoid 
deficiency. For example, lethargy and weakness can indicate either glucocorticoid 
deficiency or mineralocorticoid deficiency and occasionally, mineralocorticoid excess.  
1.6.2 Electrolytes 
Drugs such as DOCP and fludrocortisone acetate reduce potassium concentrations and 
increase sodium concentrations. Therefore, hypernatraemia and hypokalaemia are 
markers of mineralocorticoid excess and these are most commonly seen around day 10 
following an injection of DOCP around the time of peak action or at any point during 
treatment with fludrocortisone acetate. In contrast, hyperkalaemia or hyponatraemia 
indicate mineralocorticoid deficiency.  
The aim throughout therapy is to maintain sodium and potassium concentrations within 
their respective reference ranges, ideally within the middle third of the range (Lathan 
and Thompson, 2018, Adler et al., 2007).  
Sodium:potassium ratios have been used to both diagnose hypoadrenocorticism but also 
to monitor therapy. A sodium:potassium ratio of 27-32 has been suggested by the 
manufacturers of Zycortal® (Farr et al., 2020) to be an appropriate target range from 
patients receiving this drug. This is based on studies which show 27 to be a sensitive 
marker for mineralcorticoid deficiency (Adler et al., 2007, Scott-Moncrieff, 2015, 
Nielsen et al., 2008, Roth and Tyler, 1999). The upper limit of the “normal” ratio range 
is 40 (Scott-Moncrieff, 2015), meaning 32 is an arbitrary number and there is no 
evidence suggesting that dogs with sodium:potassium ratios <32 are clinically better 
controlled than those with higher rations. 
1.6.3 Plasma ACTH concentrations 
Although plasma endogenous ACTH concentrations have been shown to be high in 
patients with untreated hypoadrenocorticism (Zeugswetter and Schwendenwein, 2014, 
Lathan et al., 2014), it is unknown if endogenous ACTH concentrations are of benefit in 
assessing clinical control in patients being treated for hypoadrenocorticism. Studies in 
human medicine show that exogenous glucocorticoid therapy results in HPA 
suppression (Russell et al., 2010, Paragliola et al., 2017) and therefore endogenous 
ACTH concentrations could be of clinical utility. 
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1.6.4 Plasma renin activity  
Plasma renin activity provides additional information on mineralocorticoid control 
(Baumstark et al., 2014a). Plasma renin activity reflects mineralocorticoid 
supplementation as patients with untreated hypoadrenocorticism have hypovolaemia 
and reduced glomerular filtration rate (Scott-Moncrieff, 2015). This results in an 
increase in renin activity. It is unknown if patients with excessive mineralocorticoid 
supplementation have undetectably low renin activity due to a negative feedback 
response. 
1.6.5 Blood pressure 
Blood pressure has been studied in 8 dogs on treatment with DOCP for management of 
hypoadrenocorticism (Kaplan and Peterson, 1995). None of the dogs developed systolic 
or diastolic arterial hypertension during the 105 day study period (measured on days 0, 
30, 60, 75, 90, and 105). Patients with mineralocorticoid over-supplementation 
(particularly DOCP overdose) are expected to be hypernatraemic and this leads to 
excessive water retention in the kidneys. None of the dogs in the Kaplan and Peterson 
study were considered to be over supplemented with DOCP at a standard dose of 
2.2mg/kg every 30 days and therefore it is unknown whether or not blood pressure is 
affected by overdose of this drug. 
1.7 Prognosis 
In dogs with naturally occurring autoimmune destruction of their adrenal glands, the 
long term prognosis is good, depending on timely diagnosis and management of the 
condition. Age at diagnosis, breed and sex did not affect prognosis and the median 




1.8 Study design 
Effectiveness studies are used to compare the efficacy of two different drugs and 
include superiority trials, equivalence trials and non-inferiority trials. Although in most 
circumstances it would be preferable to show superiority of one drug compared to 
another, this is often not practically possible as the numbers needed from superiority 
power calculations are not attainable, particularly in veterinary medicine. Therefore one 
drug instead can be shown to be non-inferior to another, meaning its success is not 
clinically significantly worse than other (Evans, 2010). In addition, many drugs have 
practical benefits over another such as reduced dosing frequency or expense and often 
the main aim is to show that a test drug is “no worse than” a control drug, rather than 
being more effective (Schumi and Wittes, 2011). 
 
One of the key steps in designing a non-inferiority study is deciding the non-inferiority 
margin (effectiveness margin or delta). There are numerous methods for this, however 
in around 60% of published human medical non-inferiority trials, the method is not 
defined which is a failing of these studies (Althunian et al., 2017). In a recent review of 
the human literature, 36.5% of studies that did define how the non-inferiority margin 
was calculated, reported that the decision was based upon expert clinical opinion 
(Althunian et al., 2017). This means that rather than a formal statistical approach, 
experts instead decide upon a percentage difference in success between two drugs (the 
active control and the test drug), which is considered clinically acceptable. This 
percentage difference takes into consideration various factors including how efficacious 
the control drug is, how much efficacy needs to be retained and the importance of 
benefits the test drugs may have. For example, if a control drug has a large impact on a 
patient’s quality of life (ie the effect of the control drug compared to placebo is large), 
the percentage difference between the test drug and the control drug must be small. If a 
control drug has a smaller impact on quality of life and the patient’s health is less reliant 
on this drug (ie there is less difference in effect between the control drug compared to 
placebo), then a larger reduction in efficacy of the test drug compared to the control 
drug may be accepted in exchange for test drug benefits such as increased palatability or 
reduced dosing frequency (Food and Drug Administation, 2016). 
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The approach of defining the non-inferiority margin based on expert clinical opinion is 
common in veterinary medicine. This is as a statistical approach to defining the margin 
relies on analysis of the outcome of previous studies and often the literature is not 
sufficient for reliable statistical analysis. In 2010, the US Food and Drug Administration 
(FDA) drafted guidelines (later revised in 2016) on how to define the margin based on 
clinical and statistical considerations. These guidelines describe the fixed margin 
approach (also known and to 95%-95% method) and the synthesis approach and these 
methods should be used where possible (Food and Drug Administation, 2016). 
The non-inferiority margin must be set before sample size is considered, as non-
inferiority power calculations require: the significance level (alpha), the power level (1-
beta), the success of the control drug in previous studies, the success of the test drug in 
previous studies and the non-inferiority limit (Food and Drug Administration, 2015). 
For interpreting the non-inferiority results, set criteria must be established to define 
success and these same criteria apply for both groups. The 95% confidence interval of 
the difference between the successes of the two drugs is then calculated. For non-
inferiority, the lower bound of this confidence interval must be within the non-
inferiority margin (Oczkowski, 2014). 
1.9 Aims 
The aim of this study was to compare the efficacy of fludrocortisone acetate and DOCP 
in the management of canine patients with spontaneous hypoadrenocorticism. Although 
both treatments have been shown to be successful in controlling clinical signs of the 
condition (Lynn et al., 1993, Lynn and Feldman, 1991, Lathan and Thompson, 2018, 
Lathan et al., 2008), the two drugs have never been directly compared. Instead, dogs 
have been switched from one drug to another following treatment failure (Van Zyl and 
Hyman, 1994).
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2 Materials & Methods 
2.1 Hypothesis 
The hypothesis of this study was that treatment with a 25mg/ml prolonged-release 
suspension for injection of DOCP (the interventional product) with prednisolone, was 
not inferior to treatment with fludrocortisone acetate 0.1mg tablets (the control product) 
in the management of canine hypoadrenocorticism.  
The null hypothesis was that the treatment success (percentage of dogs with normal 
concentrations of sodium and potassium and no clinical signs) at each observation point 
on fludrocortisone, is 22% or more than the percentage reported as on DOCP with 
prednisolone.  
The alternate hypothesis was that the treatment success (percentage of dogs reported as 
having normal concentrations of sodium and potassium or having clinical signs) at each 
observation point on DOCP with prednisolone is less than 22% of the percentage 
reported when on fludrocortisone. 
2.2 Study design 
The study was carried out at the Small Animal Hospital, University of Glasgow, 
between January 2016 and January 2017. This study was a single-site, randomised, non-
masked, cross-over design study (Freise et al., 2013, Huitfeldt et al., 2011). Masking 
was not possible as the DOCP and fludrocortisone are given by different routes and the 
fludrocortisone requires daily dosing at home. A placebo arm of the trial was also not 
possible as withholding treatment in hypoadrenocorticism can lead to fatal 
decompensation. Ethical approval was granted by the University of Glasgow Ethics 
Committee and the study was conducted following the receipt of an Animal Test 
Certificate (Type B) [ATC-B] from the Veterinary Medicine Directorate. 
2.2.1 Determination of sample size 
Power calculations were performed using an online randomisation tool 
(www.sealedenvelope.com) to assess the number of dogs required to be recruited to 
show non-inferiority of the investigational product compared to the control product, 
based on previous studies on the efficacy of DOCP (Kintzer and Peterson, 1997b, 
Melian and Peterson, 1996, Farr et al., 2020). To show superiority, an impractical 
number of dogs would be required to be enrolled as canine hypoadrenocorticism is an 
uncommon condition. Therefore it was decided that a non-inferiority study would be 
more appropriate and would still address the hypothesis.  
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The expected success of the DOCP was 86% (Farr et al., 2020) and for the 
fludrocortisone was 84% (Melian and Peterson, 1996, Kintzer and Peterson, 1997b).  
Alpha (the significance level) was set at 5% and the non-inferiority margin was set at 
22%, as the lead investigator felt that a difference in success of this level would be 
clinically significant, meaning that the investigational product would result inadequate 
management of hypoadrenocorticism. It was found that thirty dogs in a crossover design 
would provide more than 80% power to investigate the hypothesis. This means that if 
the success of the experimental product was more than 22% less than the control 
product, the experimental product would be considered non-inferior.  
2.2.2 Treatment Groups 
There were two treatment groups (A and B) with a cross over at the midpoint of the 
study, following a transition (washout) phase. Group A dogs began the trial on DOCP 
and concluded the trial on fludrocortisone. Group B dogs began the trial on 
fludrocortisone before starting DOCP following the crossover. Fludrocortisone was 
given to all patients during the transition period. Patients were randomly assigned at the 
point of entry to each group using a computer generator, at a ratio of 1:1. 
2.2.3 Study and visit schedule  
The dogs were started on treatment with either DOCP and prednisolone (Group A) or 
fludrocortisone (Group B) and continued this treatment for three months, before 
embarking on a 28 day washout period (during which time they were treated with 
fludrocortisone). They then received three months of the alternative treatment. Figure 1 
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Figure 1. Diagrammatic representation of the Study Design  
Figure 1a. Original Study Design  
The treatment course of dogs allocated to groups A and B before Florinef® came off the market. 
This shows the 4 week washout period during the cross over for dogs in both groups, meaning 
dogs in group B being treated with fludrocortisone stayed on this medication for an extra month 
before receiving their first injection of DOCP. Therefore, the length of the trial was the same for 
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Figure 1b. Design after Florinef® became unavailable  
The study design after Amendment 2, which was an adjustment made to the Study Protocol 
after Florinef® came off the market. Following this, generic fludrocortisone was used which was 
significantly more expensive. Therefore the 4 week washout period was lost in group B dogs 
which were treated with fludrocortisone, as this was not required. The washout period in these 
dogs was only to keep the trial length equal in all dogs. The dogs in group B finished the trial 
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At the initial consultation, a full clinical examination was performed and 
echocardiography, blood pressure, haematology, biochemistry, T4/TSH, ACTH and 
renin samples were all submitted. Ten days after the start of each phase, a full clinical 
examination, blood pressure and electrolytes were checked.  Patients were checked 
every 28 days from the first visit. A full check as per the initial visit was performed at 
the end and start of each phase. Table 1 and Table 2 on summarise which tests were 
carried out at each visit. 
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Table 1. Study Schedule 
This study schedule illustrates each phase of the trial, when each visit was expected to take 
place, tests run at each phase and the treatment given, depending on the group allocation. 
 
 





















Phase 2: DOCP 
‡ 
   A0  ⃰ 0-13   X †   Fludrocortisone 
administered 
twice daily until 
the last dose on 







A1 1   X †  X  DOCP 
administered 
B1  8–10 X  	
C1 28 X  DOCP 
administered 
D1 56 X  DOCP 
administered 













B2 93 X  Fludrocortisone 
administered 
twice daily; last 
dose on the day 
of Visit E2 
 
C2 109–112 X  DOCP 
administered 
D2 140 X  DOCP 
administered 
E2 168 X X  
*Only for dogs assigned to Group B. 
† Included completion of Owner informed consent agreement on Day -13 for dogs in Group B 
and Day 1 for dogs in Group A. 
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Table 2. Summary of data collected at each visit 
This table summarises the samples collected at each visit and whether the results were used as 
a primary outcome measure (primary parameter) or secondary outcome measure (secondary 
parameter). 
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2.3 Case selection 
All dogs were actively recruited from first opinion practices. Practices in the South 
West of Scotland were contacted and asked to recruit patients being treated with 
fludrocortisone for treatment of hypoadrenocorticism. Permission was obtained to 
contact the owners directly to discuss the study protocol and to request consideration of 
patient enrolment. Before enrolment, case histories were thoroughly checked to ensure 
compliance with the inclusion criteria. Informed consent was obtained from all owners 
before patient enrolment on the study. In particular, this emphasised the risks involved 
in transitioning patients on to a new medication and the requirement for increased 
vigilance and record keeping.  
2.3.1 Inclusion criteria 
For inclusion, dogs had to have been diagnosed at least 60 days before enrolment on the 
trial. Diagnosis had to have been made following documentation of a lack of response to 
synthetic ACTH during an ACTH stimulation test, with cortisol samples submitted to a 
reference laboratory. They also had to be on twice daily treatment with fludrocortisone 
(at the same dose for at least 30 days before enrolment), with electrolytes within their 
respective reference ranges at the time of the first visit. Dogs were not excluded if they 
were on prednisolone therapy at the time of enrolment. Dogs also had to be amenable to 
blood sampling and travelling to the study site regularly. Finally, they had to be a 
minimum of 5kg in weight given the volume of blood sampled at each visit.  
2.3.2 Exclusion criteria 
Dogs were excluded if they were enrolled in any other studies using an investigational 
product, if they were pregnant or lactating, had signs of primary hepatic failure, signs of 
renal insufficiency (azotaemia and isothenuria), diagnosed with congestive heart failure, 
on any other immunosuppressive therapy (eg for skin disease or other autoimmune 
conditions) or on any other steroid preparations (excluding oestriol for management of 
urinary incontinence) other than that prescribed for use in the study. Patients with 
concurrent diabetes mellitus, hypothyroidism or urinary incontinence were not excluded 
provided patients were considered stable on treatment of these conditions and only one 
of these conditions had been diagnosed. 
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2.3.3 Recording of data and study monitoring 
Each case was assigned a folder containing a visit schedule and the relevant forms to be 
completed at each visit. A full clinical examination was performed and recorded, along 
with blood pressure, at each visit. All treatments were recorded at each visit, as well as a 
questionnaire regarding drug side effects. Each page of the folder was signed and dated 
by the veterinarian conducting the check. At each visit, the owner also completed a 
quality of life questionnaire. During and at completion of a trial, all the data were 
independently checked for errors and omissions. 
2.4 Treatment 
2.4.1 Control product 
Fludrocortisone acetate 0.1mg tablets were used in this study. These were either a 
generic formulation (Aspen) or Florinef® (Bristol Squibb Myers). The latter product 
required refrigeration however the former did not. Neither of these drugs are licensed 
for use in dogs for the treatment of hypoadrenocorticism. These medications were given 
orally at home by the owner, twice a day. Owners were asked to record each time the 
medication was administered to confirm adherence to the study protocol. If on only 
once daily administration before study recruitment, patients were transitioned onto 
twice daily dosing for at least two weeks before starting the trial. The dose used was 
pre-determined by each patient’s individual requirements, depending on the dose which 
resulted in electrolyte concentrations within the normal range and the absence of clinical 
signs of hypoadrenocorticism. Doses were unchanged during the study, unless patients 
developed electrolyte concentrations out with their respective normal reference ranges.  
2.4.2 Interventional product 
A 25mg/ml prolonged release suspension for injection of desoxycorticosterone pivalate 
(DOCP, Zycortal®, Dechra Ltd.) was used. This is a licensed drug for the management 
of hypoadrenocorticism in canine patients. Handling considerations include gentle 
inversion of the bottle to re-suspend the product before injection. The DOCP was stored 
at room temperature at the study site.  
The DOCP was administered every 28 days by subcutaneous injection, by one of four 
experienced vets. The initial starting dose was 2.2mg/kg in all patients, with doses being 
tailored to each patient’s individual requirements during the study, based on electrolyte 
concentrations at day 10 post-injection and clinical signs.  
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As DOCP is a pure mineralocorticoid, glucocorticoid supplementation was also required 
with the DOCP. Prednisolone tablets (1mg, 5mg and 25mg) were administered once 
daily by the owner at home. Owners were asked to record each time the medication was 
administered to confirm adherence to the study protocol. The starting dose was 
0.2mg/kg orally, once a day. Doses were adjusted based on clinical signs of 
glucocorticoid excess (polyuria, polydipsia, polyphagia, panting and coat growth) and 
deficiency (lethargy and gastrointestinal signs). The dose was increased by up to 100% 
during times of stress during the study. 
2.4.3 Dose adjustments 
Either a European Specialist in Small Animal Internal Medicine or a Resident in Small 
Animal Internal Medicine made dose adjustments. Owners were strictly prohibited from 
making dose adjustments of prednisolone at home, regardless of drug-related side 
effects. Prednisolone dose adjustments were made purely on the presence of clinical 
signs of glucocorticoid over or under dose. Hyperkalaemia or hyponatraemia would 
prompt dose increases and hypokalaemia or hypernatraemia would prompt dose 
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Table 3. DOCP dose adjustments; original plan 
This table shows the original plan for making dose DOCP adjustments, prior to the study 
amendment, which allowed larger dose reductions. 
 
Na:K	Ratio	 Dose	Adjustment	
>34	 Decrease dose to 2.0mg/kg 
32	to	<34	 Decrease dose to 2.1mg/kg 
27	to	<32	 Continue 2.2mg/kg 
24	to	<27	 Increase dose to 2.3mg/kg 





2.4.4 Concurrent Medications 
Concurrent medications for management of conditions other than hypoadrenocorticism 
were not excluded during the study period. However, drugs which could interfere with 
the study objectives were prohibited. These included potassium depleting diuretics 
which could result in hypokalaemia and any steroid preparations other than those 
prescribed for use in the study.  
2.5 Monitoring 
2.5.1 Blood pressure 
Blood pressure was measured at each visit using a Cardell Veterinary Monitor (Model 
9401). This is a validated oscillometric method of blood pressure measurement 
(Mitchell et al., 2010, Bosiack et al., 2010, Sawyer et al., 2004). The cuff was placed at 
the tail base with patients standing. Cuff size was recorded to ensure consistency in 
sampling and an average was taken of five readings for analysis.  
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2.5.2 Blood sampling 
Jugular blood samples were taken from all patients. Where possible, 10 millilitres of 
blood was obtained to ensure adequate volumes for the necessary tests. Any residual 
blood was stored at -20oC and later -80oC for future sampling if required, for one year 
after trial completion. A portion of residual EDTA anti-coagulated blood was separated 
before freezing, to allow measurement of plasma ACTH and plasma renin activity.  
2.5.2.1 Routine haematology and biochemistry  
Samples for routine haematology and biochemistry were obtained in EDTA and lithium 
heparin tubes respectively. These were submitted to the Veterinary Diagnostic Services 
laboratory, Glasgow, for reference haematological and biochemical results (ADIVA 120 
Haematology Analyser, Siemens and AU640 Series Analyser, Olympus). Samples were 
run within 48 hours of collection and were stored at 4oC if samples were not being 
processed immediately.  
2.5.2.2 Electrolytes 
The electrolytes were measured using an in-house analyser (Catalyst Dx, IDEXX One 
IDEXX Drive, Westbrook, Maine 04092) and on the basis of these results the doses of 
DOCP or fludrocortisone were adjusted as necessary. In addition, the electrolytes were 
also measured within 48 hours using a commercial laboratory analyser (Olympus 
AU640 series or Siemens Dimension Xpand Plus).  
2.5.2.3 ACTH concentrations  
Blood was collected in EDTA anti-coagulated tubes which were separated within 15 
minutes, with the plasma transferred into a plain tube before storage at -80oC. Samples 
were labelled and shipped to Nationwide Specialist Laboratories, Cambridge, in 
batches. The maximum storage time was six months. ACTH was measured using a 
competitive enzyme linked immunoassay (Canine ACTH ELISA, Biomerica Inc, 17571 
Von Karman Avenue, Irvine, CA 92614, USA. Product Ref: 7023) (Scott-Moncrieff et 
al., 2003).  
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2.5.2.4 Plasma renin activity  
Samples were handled as for plasma ACTH measurement. Renin was measured using a 
previously validated plasma renin activity radioimmunoassay (GammaCoat, Plasma 
Renin Activity Kit, DiaSorin Via Crescentino SNC, 13040 Saluggia, Italy. Product Ref: 
CA1533) (Locsei et al., 2009, Martinez et al., 2017). Each sample was measured in 
duplicate and the mean of the results used. Where the co-efficient of variation between 
the two values was greater than 15%, the test was repeated.  
2.6 Outcome measures 
2.6.1 Primary Outcome Measures 
Effectiveness was assessed primarily based on sodium and potassium concentrations 
when measured every four weeks throughout the study period. These were used to 
assess the efficacy of mineralocorticoid supplementation. The frequency of clinical 
signs of glucocorticoid excess (polyuria, polydipsia, polyphagia, panting and poor coat 
re-growth) and deficiency (lethargy and gastrointestinal signs) were used to assess 
glucocorticoid supplementation.  
2.6.2 Secondary outcome measures 
Additional assessment of outcome was made by endocrine (ACTH and plasma renin 
activity) and blood pressure assessment. Haematology and biochemistry results were 
analysed to provide supplementary information however were not used as primary 
outcome measures. 
2.7 Statistical analysis  
2.7.1 Data analysis 
All data was recorded on an Excel spreadsheet. Statistical analysis was performed using 
a statistical software package (Minitab 19.2, Minitab LLC, USA). The Anderson-
Darling test was used to assess for normality for each variable at each time point 
assessed. Paired T-tests were used when comparing normally distributed data at 
differing time points whereas Wilcoxon Signed Rank tests were used in this instance 
when the data were not normally distributed. Spearman’s correlation was used to assess 
relationships between variables. Given the number of tests performed on the same 
variables, Bonferroni correction was performed to adjust the P value and reduce the risk 
of Type I errors.  
MATERIALS & METHODS 
47 
2.7.2 Primary Outcomes 
The primary variables were i) the number of dogs with electrolytes concentrations 
within their respective reference ranges and ii) showing no clinical signs of over or 
under dosing of hypoadrenocorticism at each visit during the trial. Non-inferiority of the 
efficacy of interventional product (DOCP) vs control product (fludrocortisone) was 
evaluated by calculating a two-sided 95% confidence interval on the difference between 
the success rates in the interventional product and control product groups. The lower 
bound of this confidence interval had to be within the set margin of difference (22%; the 
non-inferiority margin), before the interventional product could be considered non-
inferior to the control product. This margin of difference was defined by the lead 
investigator, as the percentage difference between success that would begin to cause 
clinical detriment to patients. 
2.7.2.1 Electrolytes 
The proportion of both the potassium and the sodium concentrations that were outwith 
their respective reference ranges at the end of each phase of the trial were compared 
using the Chi-square test. In addition, a Chi-square test was used to compare the sodium 
and potassium concentrations out with the reference range after ten days on each trial 
phase versus the end of each trial phase. Descriptive statistics were then used to assess 
whether these electrolyte abnormalities were more consistent with over or under control 
of hypoadrenocorticism.  
The sodium and the potassium concentrations at the end of each trial phase were 
compared using Paired T-tests or Wilcoxon Signed Rank tests, depending on their 
respective distributions.   
The relationship between treatment (DOCP and fludrocortisone) doses in mg/kg was 
compared to the sodium and the potassium concentrations using Spearman Correlation.  
The number of dogs with abnormal Na/K ratios and the number of these dogs with 
electrolyte concentrations outwith their respective reference ranges were reviewed 
descriptively.  
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2.7.2.2 Clinical Signs  
The presence of clinical signs suggestive of glucocorticoid overdose (polyuria, 
polydipsia, polyphagia, excessive panting and coat changes), mineralocorticoid 
overdose (polyuria, polydipsia, weakness) and glucocorticoid and mineralocorticoid 
deficiency (vomiting, diarrhoea, weakness) were reviewed at each visit with the 
patient’s owner. If signs such as polyuria and polydipsia were considered to be more 
severe around day 8 to 12, with subsequent subsidence, these signs were considered 
more likely to be due to mineralocorticoid excess. If the signs were persistent then they 
were considered to be due to glucocorticoid excess and prednisolone doses were 
adjusted accordingly. The severities of the clinical signs were subjectively scored from 
1 to 4 (1 being absent and 4 being severe). For statistical analysis, dogs were considered 
to have absent (score 1), mild (score 2) or clinically significant (scores 3 and 4) clinical 
signs. The cumulative score of each clinical sign in every patient was calculated for 
each phase of the trial. 
Descriptive statistics were used to compare groups between the two phases of the trial 
and Chi-square tests were used to compare the number of dogs with clinical signs at 
these time points.   
2.7.3 Secondary Outcomes  
2.7.3.1 ACTH 
The ACTH concentrations were compared at the start and at the end of each phase for 
each patient, using a Wilcoxon Signed Rank test. They were also compared between the 
end of each trial phase using this test. The ACTH concentrations were compared to the 
prednisolone dose in mg/kg, using Spearman Correlation. Clinical signs of 
glucocorticoid excess were compared to ACTH concentrations descriptively, as were 
signs of hypoadrenocorticism (glucocorticoid deficiency). 
2.7.3.2 Renin 
The renin concentrations were compared at the start and at the end of each phase, using 
a Wilcoxon Signed Rank test. They were also compared between the end of each trial 
phase using this test. The relationship between the renin concentrations and DOCP dose 
in mg/kg, was assessed using Spearman correlation. Clinical signs of mineralocorticoid 
excess were compared to renin concentrations descriptively, as were signs of 
hypoadrenocorticism (mineralocorticoid deficiency). 
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2.7.3.3 Blood pressure 
The relationship between blood pressure (systolic blood pressure in mmHg) and renin 
concentrations, the DOCP dose (mg/kg) and the fludrocortisone dose (mg/kg) were all 
assessed using individual Spearman’s correlations. Blood pressure was also compared 
between the end of each phase of the trial using a paired T-test.  
For descriptive analysis, blood pressures were given a score of 0 to 2, with 0 
representative of normotensive or minimal risk of target organ damage (TOD) patients 
(systolic pressure <160mmHg), 1 representing moderate TOD risk (systolic pressure 
160-180mmHg) and 2 representing severe TOD risk (systolic pressure >180mmHg).   
2.7.3.4 Haematology and biochemistry  
Paired T tests and Wilcoxon Signed Rank tests were used to compare the neutrophil, 
lymphocyte and eosinophil counts at the end of each phase of the trial. These tests 
(depending on distribution) were also used to compare the urea, creatinine, albumin, 
glucose and calcium concentrations at the end of each phase of the trial. Although full 
haematology and biochemistry profiles were run, these variables were considered the 




3.1 Patients enrolled 
3.1.1 Signalment 
A total of 33 animals were recruited. The breeds, ages and genders were typical for 
hypoadrenocorticism when compared to those reported in the literature (Kintzer and 
Peterson, 1994; Melian and Peterson, 1996). Breeds included five Crossbreeds 
(including three Poodle crosses), five Poodles (four Standard and one Toy), four Cocker 
Spaniels, three Labrador Retrievers, two Border Collies, two Springer Spaniels, two 
West Highland White Terriers and one of each of the following: Bearded Collie, 
Cavalier King Charles Spaniel, German Short Haired Pointer, Great Dane, Husky, Jack 
Russell Terrier, Miniature Pinscher, Tibetan Mastiff, Tibetan Terrier and Utonogan. 
There were 16 neutered females, three entire females, 13 neutered males and one entire 
male. The median age was six years (range 0.5 to 12 years) and the median weight was 


















Table 4. Patient Signalments 










1	 11	 9	 Crossbreed	 FN	 11.1	
2	 0.5	 0.5	 Labradoodle	 F	 14.8	
3	 10	 7	 Jack	Russell	Terrier	 FN	 7.6	
4	 4	 1	 Great	Dane	 MN	 69.0	
5	 4	 2	 Cocker	Spaniel	 FN	 12.8	
6	 7	 3	 Great	Dane	cross	 FN	 49.4	
7	 12	 9	 West	Highland	White	Terrier	 MN	 10.6	
8	 4	 2	 Labradoodle	 FN	 40.0	
9	 9	 6	 Crossbreed	 MN	 27.5	
10*	 9	 9	 Bearded	Collie	 MN	 21.2	
11	 7	 3	 Tibetan	Mastiff	 FN	 30.8	
12	 5	 2	 WHWT	 FN	 6.3	
13	 7	 3	 Standard	Poodle	 MN	 25.0	
14	 4	 3	 Standard	Poodle	 MN	 33.1	
15	 7	 7	 Labrador	 MN	 33.5	
16	 8	 7	 Springer	Spaniel	 FN	 18.9	
17*	 11	 8	 Cocker	spaniel	 MN	 16.1	
18	 10	 7	 Working	Cocker	Spaniel	 MN	 15.6	
19	 9	 2	 Toy	Poodle	 MN	 7.6	
20	 3	 1	 German	Short	Haired	Pointer	 MN	 31.3	
21	 9	 3	 Standard	Poodle	 MN	 33.6	
22	 6	 4	 Border	Collie	 F	 18.5	
23	 5	 3	 Tibetan	Terrier	 MN	 9.3	
24	 2	 0.5	 Standard	Poodle	 MN	 24.7	
25	 5	 4	 Utanagon	 F	 22.90	
26	 3	 2	 Bearded	collie	 MN	 20.30	
27	 1	 0.5	 Labrador	 F	 32.80	
28*	 7	 6	 Springer	Spaniel	 M	 29.4	
29	 4	 4	 Bearded	Collie	cross	 F	 14.30	
30	 6	 3	 Cavalier	King	Charles	Spaniel	 FN	 11.30	
31	 3	 2	 Husky	 MN	 40.20	
32 9 2	 Labrador	 FN 42.10 
33 3 2	 Miniature	Pinscher	 FN 5.90 
*Patients excluded 
Dx = diagnosis 
M; male, MN; male neuter, F; female, FN; female neuter  
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Table 5. ACTH stimulation results and fludrocortisone dose at enrolment 
This table summarises the group each patient was assigned to, their initial ACTH stimulation 
test results, the duration of treatment prior to enrolment and the fludrocortisone dose at 
















Dose of fludrocortisone 
at enrolment 
 (mg, twice daily) 
1 A <7 <7 653 0.1 
2 B <10.5 <10.5 57 0.3 
3 A <14 <14 1087 0.1 
4 B 14 72 1076 1.0 
5 A 27 42 690 0.3 
6 B <7 <7 1243 0.6 
7 A 18 14 1008 0.4 
8 A <7 <7 806 0.4 
9 A <6.9 <6.9 768 0.2 
11 B 30 35 1149 0.3 
12 A <6.5 <6.5 1079 0.1 
13 B <10.5 <10.5 1270 0.3 
14 B <7 <7 602 0.4 
15 B <7 <7 89 0.3 
16 A 44 45 518 0.2 
18 B 19.5 22.4 1099 0.4 
19 B <5.6 <5.6 2421 0.1 
20 B 27.6 27.6 840 0.4 
21 B <7 <7 2115 0.2 
22 A 34 38 585 0.2 
23 A <10 <10 553 0.1 
24 B <27.6 <27.6 392 0.3 
25 A 13.5 <10.5 229 0.25 
26 B <10 <10 67 0.2 
27 A 7.2 7.92 379 0.25 
29 A <14 <14 125 0.1 
30 A <7 <7 1036 0.3 
31 B <6.9 <6.9 612 0.4 
32 A 19 21 2516 0.1 





Table 6. Summary of pre-trial patient data 
Summary of patients, including their age at diagnosis, age at the start of the trial, signalment, 


















1	 A	 11	 9.6	 Crossbreed	 FN	 11.1	 0.009	 154	 4.1	
2	 B	 0.5	 0.5	 Labradoodle	 F	 14.8	 0.020	 148	 4	
3	 A	 10	 7.2	 JRT	 FN	 7.6	 0.013	 152	 4.5	
4	 B	 4	 1.9	 Great	Dane	 MN	 69.0	 0.014	 147	 5.4	
5	 A	 4	 2.5	 Cocker	
Spaniel	
FN	 12.8	 0.023	 149	 4.5	
6	 B	 7	 3.8	 Great	Dane		 FN	 49.4	 0.012	 153	 5.3	
7	 A	 12	 9.4	 WHWT	 MN	 10.6	 0.038	 148	 6.5	
8	 A'	 4	 2.3	 Labradoodle	 FN	 40.0	 0.022	 149	 4.7	
9	 A	 9	 6.9	 Crossbreed	 MN	 27.5	 0.005	 155	 4.8	
11	 B	 7	 3.9	 Tibetan	
Mastiff	
FN	 30.8	 0.010	 154	 4.2	
12	 A'	 5	 2.2	 WHWT	 FN	 6.3	 0.011	 152	 4.5	
13	 B	 7	 3.7	 Standard	
Poodle	
MN	 25.0	 0.012	 150	 4.2	
14	 B	 4	 3.2	 Standard	
Poodle	
MN	 33.1	 0.012	 153	 4.2	
15	 B	 7	 7.5	 Labrador	 MN	 33.5	 0.009	 152	 4.8	
16	 A	 8	 7.3	 Springer	
Spaniel	
FN	 18.9	 0.007	 150	 4.8	
18	 B	 10	 7.1	 Working	
Cocker		
MN	 15.6	 0.026	 153	 3.5	
19	 B'	 9	 2.4	 Toy	Poodle	 MN	 7.6	 0.012	 145	 5.5	
20	 B	 3	 1.2	 GSHP	 MN	 31.3	 0.020	 148	 4.9	
21	 B	 9	 3.9	 Standard	
Poodle	
MN	 33.6	 0.013	 154	 4.4	
22	 A'	 6	 4.8	 Border	Collie	 F	 18.5	 0.009	 151	 4.2	
23	 A'	 5	 3.6	 Tibetan	
Terrier	
MN	 9.3	 0.003	 153	 4.6	
24	 B'	 2	 0.1	 Standard	
Poodle	
MN	 24.7	 0.010	 152	 4.4	
25	 A'	 5	 4.6	 Utanagon	 F	 22.90	 0.017	 149	 4.5	
26	 B'	 3	 2.9	 Bearded	
collie	
MN	 20.30	 0.010	 152	 4.6	
27	 A'	 1	 0.8	 Labrador	 F	 32.80	 0.022	 152	 4.6	
29	 A'	 4	 4.5	 Crossbrred	 F	 14.30	 0.002	 152	 4.5	
30	 A'	 6	 3.6	 CKCS	 FN	 11.30	 0.051	 145	 4.3	
31	 B	 3	 2.1	 Husky	 MN	 40.20	 0.007	 156	 5.7	
32 A 9	 2.5	 Labrador	 FN 42.10 0.016 148	 3.8	
33 A 3	 2.9	 Miniature	
Pinscher	




















Dx – Diagnosis 
FL Dose – Fludrocortisone mg/kg twice a day  
F- Female 
FN – Female Neutered 
M- Male 
MN – Male Neutered 
JRT – Jack Russel Terrier 
WHWT – West Highland White Terrier 
GSHP – German Short Haired Pointer 
CKCS – Cavalier King Charles Spaniel  




Table 7. Pre-trial data Group A vs B 
This table shows the Pre-trial data comparison between Groups A and B. Means are shown for 
normally distributed data and medians for abnormal distribution. Significance is marked by an *. 
  Group A Group B P value 








Mean	 4.7	 3.2	 	
Standard	deviation	 2.7	 2.2	
	 0.099	
Weight at start 
(kg) 




Age at Day 1 
(years) 





twice a day) 




Sodium at the 
start 














3.1.2 Pre-existing conditions 
One patient (Patient 29) had been diagnosed with pannus two days before diagnosis of 
hypoadrenocorticism. This patient had been treated with dexamethasone, polymixin B 
and neomycin sulphate eye drops (Maxitrol, Alcon) for 13 days prior to ACTH 
stimulation and had been started on prednisolone acetate eye drops (Pred-Forte, 
Allergen Ltd) two days before this test. Given the lifelong nature of this condition, the 
eye drops were continued throughout the trial period.  
Another patient (Patient 6) had pre-existing urinary incontinence and was treated with 
oestradiol (Incurin, MSD Animal Health) throughout the study period. Although not on 
concurrent medication at the time of enrolment, one patient (Patient 15) had a pre-
existing diagnosis of a recurrent malassezia otitis externa. This had resolved by the time 
of enrolment however it had been treated with oral ketoconazole (Sporanox, Janssen-
Cilag Ltd.) and amoxicillin clavulanic-acid (Synulox, Zoetis). The patient had become 
unwell eight days following the introduction of ketoconazole, at which point this drug 
had been discontinued.  
3.1.3 Concurrent medications 
Several patients required treatment during the trial for conditions unrelated to 
hypoadrenocorticism and which weren’t suspected to be associated with side effects 
caused by either fludrocortisone or DOCP. Three patients (1, 20 and 24) had been 
prescribed amoxicillin clavulanic-acid for management of pyoderma, by their primary 
care veterinarians. Another patient (Patient 20) was prescribed amoxicillin clavulanic-
acid by its primary care veterinarian for management of a suspected urinary tract 
infection. Clindamycin was prescribed by the primary care veterinarian to Patient 1 for 
management of colitis. Malassezia otitis externa resulted in prescription of clotrimazole 
by the primary care veterinarian of Patient 28. Patient 19 was prescribed a short course 
of tramadol for management of brief hind limb lameness and Patient 25 was involved in 
a minor road traffic accident and had been treated with methadone. This patient was 
also given an increase in steroid dose (dexamethasone intravenously) following this 
incident for one dose. During the trial, Patient 11 was diagnosed with urinary 
incontinence and was started on Propalin, Vetoquinol (phenylpropanolamine). 
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Two patients required management for suspected trial drug related events. Patient 13 
required hospitalisation, fluid therapy, maropitant, potassium supplementation and 
spironolactone for lethargy, anorexia, hypokalaemia and hypotension around day 10 
following a DOCP injection. On one visit, buprenorphine was also prescribed for 
concurrent suspected pancreatitis. Patient 22 received maropitant 9 days after its third 
dose of DOCP as it had vomited once, was inappetent and lip smacking.  
3.1.4 Patients excluded 
In total, three dogs were removed from the trial. These patients had been initially 
enrolled in the study and therefore had been started on trial drugs. One dog was 
removed from the study (Patient 10) as on further evaluation of its history, it had 
emerged that hypoadrenocorticism had not been confirmed using an ACTH stimulation 
test. Instead, this condition was diagnosed purely on abnormal electrolyte 
concentrations (hyperkalaemia and hyponatraemia). As this patient had clinically and 
biochemically responded very well to steroid supplementation and as this patient was a 
young Bearded Collie, it was suspected that the diagnosis was correct. Therefore the 
patient was not weaned off glucocorticoid and mineralocorticoid therapy to confirm the 
diagnosis of hypoadrenocorticism as this was likely to be detrimental to its health. It 
was however excluded from the trial as it did not comply with the inclusion criteria.  
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Another (Patient 28) was excluded as during the initial trial screening, it was diagnosed 
with hypothyroidism with a thyroxine (T4) concentration under the detection limit of 
3.2 nmol/L (reference 15-45) with a concurrent increase in thyroid stimulating hormone 
(TSH) of 3.54 ng/ml (0-0.61). If the low T4 was due to exogenous glucocorticoid 
therapy, then the TSH would not be expected to be increased (O'Neill et al., 2011, 
Torres et al., 1991). There was a marked increase in cholesterol (17.45mmol/L) which 
was considered consistent with this diagnosis. This patient was started on levothyroxine 
and an improvement in demeanour and a reduction in cholesterol were seen. The T4 
concentrations normalised, confirming adequate management of the condition. 
Although no clinical signs of hypothyroidism had been described initially, the owner of 
this patient felt it was much brighter on thyroxine supplementation. In contrast to these 
results, patients on treatment for hypoadrenocorticism tend to have low T4 and TSH 
concentrations due to the effects that glucocorticoids have on the thyroid axis (Daminet 
and Ferguson, 2003, Reusch et al., 2017). The trial protocol allowed for patients with 
concurrent endocrinopathies, however it was a requirement that these patients be stable 
on treatment. This patient was excluded from the trial as although it became stable on 
thyroxine supplementation, it was not stable on treatment at the time of enrolment. 
Finally, one dog (Patient 17) did not complete the trial as it died suddenly one week 
after starting. This patient was in group B and therefore was not transitioned onto 
DOCP. Post-mortem examination was consistent with a haemoabdomen due to a 
ruptured haemangiosarcoma.  
3.2 Adverse events 
There were two significant adverse events. The first was that one dog (Patient 17) died 
of a ruptured splenic haemangiosarcoma, which was thought to be unconnected to the 
trial. The second was Patient 13 who developed pancreatitis whilst DOCP was being 
administered. This dog recovered. This condition could have been linked to the 
administration of the DOCP treatment but this was not definitively established and the 
dog was able to complete the trial. 
3.3 Protocol deviations 
There were two significant protocol deviations. One was that during the study period 
the branded preparation of fludrocortisone acetate (Florinef®, Bristol) became 
unavailable. Therefore a generic fludrocortisone tablet formulation (Aspen 
Pharmaceuticals) was used instead. 
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Initially the study protocol had stated that non-inferiority would be determined by 
treatment success at each visit during each phase of the trial (section 2.1) and that 
success was patients showing no signs of over or under dosing of each drug. However 
during the study, the success criteria was changed. Success was defined as patients 
showing no signs (clinical or electrolyte abnormalities) suggestive of steroid under dose 
and at the end of the trial only.  
3.4 Study results 
3.4.1 Study Design 
There was one significant Protocol Amendment during this trial which was required 
following withdrawal of Florinef® (Bristol Squibb Myers) from the market. Generic 
fludrocortisone (Aspen) was administered instead which was significantly more 
expensive. Therefore dogs in Group B who were treated with fludrocortisone did not 
require a washout period before starting the second phase of the trial and therefore were 
treated with three months of fludrocortisone followed immediately by three months of 
DOCP with prednisolone. Figure 1b illustrates this change in study design. 
During the trial it became apparent that the starting dose of DOCP (mg/kg) was too high 
for a significant number of dogs, meaning several dose reductions were required. 
Therefore unscheduled visits were arranged ten days after any dose change (see section 
3.3.4). 
Given this apparent over treatment with DOCP in many patients, the criteria for non-
inferiority was adjusted slightly. The initial Study Protocol had stated that treatment 
success would be classed as: “the percentage of dogs reported as having normal 
concentrations of sodium and potassium or having no clinical signs at each observation 
point on the trial” (see section 2.1). However, many dogs had clinical signs and 
electrolyte concentrations suggestive of over treatment. This was not considered to 
reflect on treatment success, as these patients showed no signs of under treatment or 
treatment failure. Therefore the classification of treatment success was instead 
considered to be: “the percentage of dogs reported as having no hyperkalaemia or 
hyponatraemiam with no clinical signs of hypoadrenocorticism at the end of each phase 
of the trial” (see section 3.3.8). The end of the trial was used, instead of each 




3.4.2 Groups  
There were 16 dogs in Group A (DOCP followed by fludrocortisone) and 14 dogs in 
Group B (fludrocortisone followed by DOCP). When the patient data from the two 
groups (A and B) were compared it was found that there was a significant difference in 
weight between them (Mann-Whitney U test, P= 0.016). In addition, there was a 
significant difference between the gender distribution (Chi-square Test, P= 0.013) with 
more male neutered dogs in Group B and more females in Group A. There were no 
significant differences between the two groups in the dose of fludrocortisone per kg of 
weight (Mann-Whitney U test), the age at the start of the trial, the age at diagnosis, or 
the time between diagnosis and the start of trial (all Independent T Test). There was no 
significant difference in sodium and potassium concentrations between the two groups 
at the beginning of the trial (using an Independent T Test and Mann-Whitney U Test 
respectively). Drug doses were given in mg/kg and the difference in gender distribution 
was not considered to affect the trial results. Therefore, the two groups (A and B) were 
combined to give one group and the two phases of the trial, the DOCP phase and the 
fludrocortisone phase, were considered separately.  
3.4.3 Visits 
The predicted total number of visits according to the original protocol was 300. The 
total number of visits achieved was 298. Two dogs did not attend one appointment each. 
When the A visits were excluded, the total number of visits should have totalled 240. 
The total number of these visits that were within 3 days of the expected time (i.e. 8-10 
or 28, 56, 84 days) for the B, C, D and E visit was 214 (89%). Table 8 and Figure 2 












Table 8. Summary of visits on each day of the trial 
The number of visits that occurred on each day after starting each phase of the trial for all 30 





















0	(A	visit)	 60	 	 	 	 	 	 	
1	 0	 26	 3	 51	 0	 76	 0	
2	 0	 27	 5	 52	 3	 77	 1	
3	 0	 28(C	visit)	 45	 53	 4	 78	 2	
4	 0	 29	 1	 54	 4	 79	 1	
5	 0	 30	 0	 55	 6	 80	 0	
6	 0	 31	 2	 56(D	visit)	 36	 81	 5	
7	 0	 32	 0	 57	 1	 82	 2	
8	 11	 33	 0	 58	 0	 83	 7	
9	 9	 34	 0	 59	 2	 84	(E	visit)	 30	
10	(B	visit)	 34	 35	 0	 60	 0	 85	 2	
11	 2	 36	 0	 61	 1	 86	 1	
12	 2	 37	 0	 62	 0	 87	 1	
13	 0	 38	 1	 63	 1	 88	 0	
14	 0	 39	 0	 64	 0	 89	 0	
15	 0	 40	 0	 65	 0	 90	 4	
16	 0	 41	 0	 66	 1	 91	 1	
17	 0	 42	 0	 67	 0	 92	 0	
18	 0	 43	 0	 68	 0	 93	 1	
19	 0	 44	 0	 69	 0	 94	 0	
20	 0	 45	 0	 70	 0	 95	 0	
21	 0	 46	 0	 71	 0	 96	 0	
22	 0	 47	 0	 72	 1	 97	 0	
23	 0	 48	 0	 73	 0	 98	 0	
24	 0	 49	 0	 74	 0	 99	 0	




Figure 2. Graphical representation of visits which took place on each day of each 
phase of the trial 
Bar chart of the number of dogs presenting for a visit on each day of each phase of the trial. As 
there were two phases of the trial, this meant the maximum number of dogs was 60, rather than 
30. Day 1 was the start of each phase (and does not include the washout phase). As each 
phase of the trial was 12 weeks long, the scheduled E visit would have been anticipated on day 





3.4.4 Unscheduled Visits 
There were 38 additional visits made outwith the protocol. Thirty-five of these were 
during the DOCP phase and three were during the fludrocortisone phase. Ten of these 
were conducted ten days following a DOCP dose change, to check the electrolytes were 
within the normal range and to assist in assessment of the dose change. Nine visits were 
due to the DOCP injection being brought forward or delayed given reduced or 
prolonged duration of DOCP respectively (see section 3.3.5). One dog (Patient 13) 
required seven unscheduled visits whilst on the DOCP phase to manage signs of 
mineralocorticoid overdose (hypokalaemia, hypernatraemia, hypertension) and 
pancreatitis (diagnosed based on an abnormal SnapPLTM, IDEXX test and a hypoechoic 
pancreas on ultrasound).  The remaining visits were primarily to assess the patients 
when they seemed unwell in any way, to ascertain if the illness was related to 
hypoadrenocorticism and the associated treatment.  
3.4.5 Doses of Treatment Drugs 
During the trial, 25 dogs received no change in their fludrocortisone dose, three dogs 
had a minor dose reduction and two dogs received a slight increase in their dose. One of 
the dogs that required a dose increase had been on concurrent prednisolone therapy and 
this treatment was stopped at the time of the dose increase. The three dogs who had 
fludrocortisone dose decreases were showing signs of steroid overdose such as polyuria 
and polydipsia. The median dose of fludrocortisone at the end of the fludrocortisone 
phase of the trial was 0.012mg/kg (range 0.002 to 0.040) twice daily. This was in 
comparison to a median dose of 0.015mg/kg (range 0.002 to 0.050) twice daily at the 
start of the fludrocortisone phase. 
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Twenty-eight dogs required a dose reduction at least once during the DOCP phase of 
the trial and two dogs required a dose increase. Fifteen dogs (on 25 occasions) received 
injections which were not given 28 days following the previous injection. On ten of 
these occasions, this was due to owner compliance and appointment scheduling. These 
injections were given one day early or one day late other than on three occasions when 
it was given up to four days early or late. Two dogs (Patients 7 and 21) required DOCP 
injections every 25 days as the duration of action of DOCP was not considered to be 
long enough in these patients, resulting in hyperkalaemia. Four dogs required their 
injections to be given three to seven days late given on going hypokalaemia or 
hypernatraemia at 28 days. Despite consecutive dose reductions, the duration of action 
of DOCP in these patients seemed to be prolonged. The median dose of DOCP at the 
end of the DOCP phase of the trial was 1.74mg/kg (range 1.09 to 2.6). All patients were 
started on 2.2mg/kg of DOCP subcutaneously.  
Dose reductions in prednisolone were required in 22 dogs, the dose was unchanged in 
eight dogs and increased in two dogs. Dose reductions were required due to the 
presence of a combination of polyuria, polydipsia, panting, polyphagia and coat 
changes. Prednisolone dose increases were made in two patients who had electrolytes 
within the normal reference range but seemed weak. No patients were on prednisolone 
at the end of the fludrocortisone phase of the trial. The median dose of prednisolone at 
the end of the DOCP phase of the trial was 0.13mg/kg once a day (range 0.02-0.35). 
This was in comparison to a dose of 0.21mg/kg (range 0.17 to 0.35) at the start of the 
trial.  
3.4.6 Primary Outcome Measures 
3.4.6.1 Electrolytes  
Electrolytes were assessed at each visit, regardless of the phase of trial. The sodium was 
not above reference at any point on the trial but was below reference on 5 occasions 
(range 111.8 – 135mmol/L; normal reference range 136-159). These were all during the 
fludrocortisone phase of the trial; twice during the D visit and three times during the E 
visit. The result of 111.8mmol/L was considered to be spurious because the patient was 
showing no signs of disease and a hyponatraemia of this magnitude would be 
considered to be a clinical emergency. Therefore it was excluded from all further 
analysis (revised range 134.3 – 135mmol/L; normal reference range 136-159). 
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In contrast, the potassium concentrations were low predominantly during the DOCP 
phase of the trial. The potassium was low on 13 occasions during the trial (range 2.9 – 
3.3mmol/L; normal reference range 3.4 – 5.8): 12 of these times during the DOCP 
phase and once during the fludrocortisone phase. The low potassium concentration 
during the fludrocortisone phase was at visit A1, following an injection of DOCP 56 
days earlier. During the DOCP phase, the potassium was low at the A visit once, the B 
visit three times and four times at both the D and E visits. The potassium concentration 
was increased on one occasion (5.9 mmol/L) at the A visit of the DOCP phase, whilst 
the patient was on treatment with fludrocortisone. Table 9 and Figures 3, 4 and 5 show 






















Table 9. Minimum, maximum and median sodium potassium concentrations 
during the trial. Mean and standard deviation of sodium:potassium ratios. 
The range of sodium and potassium results found on each visit, during each phase of the trial. 
Range and medians were used for data which was not normally distributed and mean and 










	 	 Sodium	(mmol/l)	 Potassium	(mmol/l)	 Sodium:potassium	
Ratio	





	 	 	 	 	 	 	 	 	
A	 30	 139.9	 153.5	 147.4	 3.1	 5.3	 4.2	 35.3	 4.99	
B	 28	 142.5	 152.2	 147.2	 3.5	 5.7	 4.4	 33.3	 4.36	
C	 30	 136.1	 152.4	 146.8	 3.5	 5.3	 4.5	 33.8	 4.19	
D	 29	 134.8	 152.3	 145.1	 3.7	 5.3	 4.4	 32.9	 3.56	
E	 30	 111.8	 150.2	 146.9	 3.4	 5.6	 4.6	 32.7	 4.25	
DOCP	
phase	
	 	 	 	 	 	 	 	 	
A	 30	 138.8	 151.7	 146.7	 3.5	 5.9	 4.4	 32.9	 4.07	
B	 30	 143.6	 154.4	 149.0	 2.9	 4.9	 3.8	 39.2	 4.81	
C	 30	 138.0	 152.9	 148.6	 3.3	 5.4	 3.8	 38.3	 4.32	
D	 30	 143.4	 153.6	 148.9	 3.1	 5.2	 3.8	 39.0	 4.88	
E	 30	 145.0	 153.1	 148.3	 3.0	 4.4	 3.7	 40.0	 3.70	
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Figure 3. Proportion of electrolytes out with the normal reference interval at ten 
days into and at the end of each trial phase 
Electrolyte results (sodium and potassium) at difference phases of the trial. More specifically, it 
shows the proportion of results above the reference range, below the reference range and 
within the reference range. The sodium reference range was 136-159mmol/L and the potassium 
reference range was 3.4-5.8mmol/L. Some bars equate to less than 30 due to results not being 








Figure 4. Sodium concentrations at each visit during trial, on each treatment 
Box and whisker plot of the sodium concentrations at each visit during each phase of the trial. 
The coloured box represents the interquartile range (Q3 to Q1; 50% of the data set) with the 
solid bar within the box representing the median result (Q2). The whiskers show the remaining 
data (the 5th to the 95th percentiles). Outliers are marked by a symbol. Outliers are observations 
















Figure 5. Potassium concentrations at each visit during trial, on each treatment 
Box and whisker plot of the potassium concentrations at each visit, during each phase of the 
trial. The coloured box represents the interquartile range (Q3 to Q1; 50% of the data set) with 
the solid bar within the box representing the median result (Q2). The whiskers show the 
remaining data (the 5th to the 95th percentiles). Outliers are marked by a symbol. Outliers are 










Comparing the two phases of the trial using a Chi-Square test, there was a significant 
difference (P= 0.020) between the proportions of potassium concentrations which were 
below the reference range at the end of the DOCP phase (17%), compared to the end of 
the fludrocortisone phase (0%). Using this test, there was no significant difference 
between proportions of the sodium or potassium concentrations out with the reference 
range after one vs. three months of either treatment (DOCP phase vs fludrocortisone 






Table 10. Proportion of electrolytes out with the normal reference interval at the B 
and E visits 
A summary of the number of electrolytes out with the normal reference range ten days into each 











































P and prednisolone phase 
B – B visit; ten days into the phase  











There was a significant difference between the sodium concentrations at the end of the 
fludrocortisone phase (mean 144mmol/L; SD 7.2) vs the end of the DOCP phase (mean 
148.2mmol/L; SD 1.8) (Paired T test; P=0.002) and between the potassium 
concentrations (Wilcoxon Signed Rank test; P=0.000) at these points (potassium at end 
of fludrocortisone phase mean 4.47mmol/L; SD 0.53 and at end of DOCP phase mean 
3.73mmol/L; SD 0.33). The sodium concentrations after one month (mean 146mmol/L; 
SD 3.3) vs after three months of fludrocortisone (144mmol/L; SD 7.2) were 
significantly different (Paired T test; P=0.017) however there was no significant 
difference between the sodium concentrations after one month vs after three months of 
DOCP (DOCP phase) or in the potassium concentrations at these time points on the 
fludrocortisone or DOCP phases of the trial. 
There was significant correlation between the DOCP dose (mg/kg) and the potassium 
concentrations (Spearman Correlation; r=0.000) at the end of the DOCP phase (Figure 
6). There was no correlation (using Spearman Correlation) between the DOCP dose 
(mg/kg) and the sodium concentrations or the fludrocortisone dose (mg/kg) with either 
the sodium or the potassium concentrations at the end of each phase of the trial (Figure 










Figure 6. Relationship between DOCP dose and sodium and potassium 
concentrations 
Scatterplot of the relationship between the DOCP dose (x axis) and the sodium (left y axis) and 
potassium (right y axis) results. Using Spearman Correlation, only the potassium results were 
















Figure 7. Relationship between fludrocortisone dose and sodium and potassium 
concentrations 
Scatterplot of the relationship between the fludrocortisone dose (x axis) and the sodium (left y 
axis) and potassium (right y axis) results. Using Spearman Correlation, these results were not 
significant. 
 































The sodium:potassium ratio was assessed as a potential indicator of mineralocorticoid 
control and overall, was not found to be useful. During the scheduled visits, when a 
normal range of 27 – 32 was used, there was an increase in the sodium:potassium ratio 
on 207 occasions. Only 60 of these visits (29%) were during the fludrocortisone phase, 
not including the first visit of the phase when DOCP had been given 8 weeks earlier. 
This reduced to 12 occasions when an upper limit of 42 was used and 3 when an upper 
limit of 46 was used. The ratio was low on seven visits when the electrolytes were 
within the normal range. This would have incorrectly led to a dose adjustment if using 
sodium:potassium ratios as a marker of control (see Table 3). In addition, on six 
occasions the sodium:potassium ratio was normal whilst the sodium was low. This 
could have resulted in continuation of a mineralocorticoid dose which was not high 
enough (during the fludrocortisone phase). There was agreement with the 
sodium:potassium ratio with the respective individual sodium and potassium 
concentrations 21 times when the potassium was low, three times when the sodium was 
low and once when the potassium was high. 
 
3.4.6.2 Clinical Signs  
3.4.6.2.1 Clinical Signs of Glucocorticoid Excess 
Polyuria, polydipsia, polyphagia, excessive panting and coat changes were used as 
clinical markers of glucocorticoid excess. Using a Chi-Square test, there was no 
significant difference between the proportion of dogs with and without clinical signs at 
the end of each phase of the trial or after one and three months of either treatment 
(DOCP and prednisolone or fludrocortisone). 
At the start of the fludrocortisone phase, the cumulative subjective score (see section 
2.7.2.2) was 93 and at the end of this phase it was 77. For the DOCP phase, the 
cumulative subjective score was 97 and at the end of the DOCP phase, the cumulative 
subjective score was 144, suggesting an increase in clinical signs of glucocorticoid 







Figure 8. Clinical signs of treatment overdose 
Figure 8a. Clinical Signs of glucocorticoid overdose 
Bar chart of the clinical signs seen on each phase of the trial, as the A, B and E visits. The 
severities of the clinical signs were subjectively scored from 1 to 4 (1 being absent and 4 being 
severe). As there were 30 patients, this meant the minimum score for each clinical signs was 30 
and the maximum score for each clinical sign was 120. Polyuria and polydipsia are included 







Figure 8b. Clinical Signs of mineralocorticoid overdose 
Bar chart of the clinical signs seen on each phase of the trial, as the A, B and E visits. The 
severities of the clinical signs were subjectively scored from 1 to 4 (1 being absent and 4 being 
severe). As there were 30 patients, this meant that the minimum score for each clinical signs 
was 30 and the maximum score for each clinical sign was 120. Polyuria and polydipsia are 







3.4.6.2.2 Clinical Signs of Mineralocorticoid Excess 
Polyuria, polydipsia, weakness and hypertension were used as clinical markers of 
mineralocorticoid excess. Polyuria and polydipsia (PU/PD) were considered separately 
from the other signs given that they are hard to distinguish from signs of glucocorticoid 
excess. Using a Chi-Square test, there was a significant difference (P=0.014) in the 
proportion of dogs with PU/PD ten days after the first DOCP injection (B visit DOCP 
phase, 79%) compared to 10 days after starting the fludrocortisone phase (B visit 
fludrocortisone phase 46%).  There was however no difference in the proportion of dogs 
with PU/PD at the B visit and E visit of either phase of the trial.  
When considering hypertension and weakness, there was a significant difference in the 
proportion of dogs with the presence of clinical signs (Chi-Square; P=0.035) at the end 
of the fludrocortisone phase (47%) compared to the end of the DOCP phase (73%). 
There was no significant difference in the proportion of dogs with clinical signs at the B 
and E visit on either phase of the trial.  
Polyuria and polydipsia could be considered signs of overdose of either treatment. 
Considering this sign only, the cumulative score (see section 2.7.2.2) was 102/240 at the 
start of the FL phase and 96/240 at the end, compared to 106/240 and 128/240 
respectively for the DOCP phase. For the remaining clinical signs of glucocorticoid 
overdose (polyphagia, coat changes and panting), the cumulative subjective score was 
141/360 at the start of the FL phase and 131/360 at the end, compared to 141/360 and 
166/360 respectively for the DOCP phase (Figure 4a). For remaining clinical signs of 
mineralocorticoid overdose (reduced appetite, lethargy and hypertension), the 
cumulative subjective score was 102/360 at the start of the FL phase and 89/360 at the 
end compared to 90/360 and 116/360 respectively for the DOCP phase (Figure 4b). 
These results suggest an increase in clinical signs of glucocorticoid and 





3.4.6.2.3 Clinical signs of hypoadrenocorticism 
One patient (Patient 13) presented with signs which could have been considered to be 
associated with untreated hypoadrenocorticism (vomiting, lethargy and weakness). This 
occurred 6 to 16 days after each injection of DOCP and was also associated with 
hypokalaemia (nadir of 3.0 mmol/L; reference range 3.4-5.8) and hypertension 
(maximum mean systolic pressure 186 mmHg, enrolment visit systolic pressure 134 
mmHg). Therefore, it was suspected that these signs were associated with 
mineralocorticoid overdose alone, rather than mineralocorticoid or glucocorticoid 
overdose. These signs resolved post injection following DOCP dose reductions. 
3.4.7 Secondary Outcome Measures 
3.4.7.1 ACTH concentrations 
ACTH was measured at the start and end of the DOCP phase in all dogs and at the start 
and end of the fludrocortisone phase in all but one dog. The ACTH concentration 
increased in two dogs, stayed the same in five and decreased in 23 dogs during the 
DOCP phase. During the fludrocortisone phase, it increased in 13 dogs, stayed the same 
in eight dogs and decreased in eight dogs. The ACTH concentration was undetectable in 
two dogs at the start of the DOCP phase (one group A and one group B) and 15 dogs at 
the end of the DOCP stage (six group A and nine group B). It was undetectable in only 
four dogs at the start of the fludrocortisone phase (all group B) and three dogs at the end 
of the fludrocortisone phase (two group A and one group B). 
The ACTH concentrations were significantly lower at the end of the DOCP phase 
(Wilcoxon Signed Rank test; P=0.000) when compared to the start but not between the 
start and end of the fludrocortisone phase. They were also significantly lower 
(Wilcoxon Signed Rank test; P=0.000) at the end of the DOCP phase compared to the 
end of the fludrocortisone phase. There was no correlation between the ACTH 
concentrations and the prednisolone dose (mg/kg) on the DOCP phase (Spearman 
Correlation). Although statistical analysis was not performed, there appeared to be no 
obvious relationship between the severity of clinical signs and complete suppression of 







Table 11. Summary of ACTH and renin results at the end of each phase of the trial 
This table shows the ACTH and renin results at the start and end of each phase of the trial. 
Each individual patient and which group they were assigned to is shown. 
 
  ACTH (pg/ml) Renin (ng/ml/h) 
















1 A 14.4 15.3 523 560 0.44 0.15 0 0 
2 B 206 2.5 384 126 2.29 0.44 20.5 24.79 
3 A 309 61 281 463 1.78 0 0.07 0.07 
4 B 175 39 105 175 15.98 1.63 15.84 15.98 
5 A 128 2.5 24 41 0.44 0.15 0 0 
6 B 28 5.7 2.5 28 2.29 0.07 4.96 2.29 
7 A 129 2.5 * 21 7.47 0.52 * 2.6 
8 A 178 20 112 286 2.74 0 0.3 8.29 
9 A 76 2.5 162 95 0.89 0 0 0.15 
11 B 310 507 218 310 0 0 0.15 0 
12 A 2.5 2.5 312 2.5 2.89 0.07 1.18 17.69 
13 B 5.1 2.5 2.5 5.1 0.74 0.07 0.07 0.74 
14 B 226 2.5 256 226 2 0 10.58 2 
15 B 81 8.6 12 81 2.4 0 0 2.4 
16 A 19.1 5.1 142 193 14.43 0.07 0.07 0 
18 B 2.5 2.5 2.5 2.5 0 0.07 0.15 0 
19 B 196 6.9 363 196 1.92 0.07 2.89 1.92 
20 B 13.1 2.5 12.7 13.1 11.91 0.07 6.51 11.91 
21 B 580 2.5 469 580 0 0 0.3 0 
22 A 217 21 281 186 12.65 0.52 0.59 25.46 
23 A 256 8.6 436 196 18.13 0.07 0.3 9.69 
24 B 63 2.5 386 63 7.55 0.07 14.95 7.55 
25 A 108 31 28 102 8.14 0.15 0 1.48 
26 B 384 2.5 109 384 14.8 1.48 17.83 14.8 
27 A 307 89 317 315 5.7 0.15 0.15 6.51 
29 A 9.2 2.5 79 2.5 23.46 0 0 46.9 
30 A 230 73 298 266 2.96 0.30 1.7 2.22 
31 B 33 2.5 2.5 33 14.5 0 1.41 14.5 
32 A 243 2.5 52 241 0.59 0 0.15 0.22 
33 B 2.5 212 9.7 221 19.83 5.70 9.69 19.61 
Median 128.5 3.8 142 180.5 2.815 0.07 0.3 2.345 
Minimum 2.5 2.5 2.5 2.5 0 0 0 0 
Maximum 580 507 523 580 23.46 19.61 20.5 46.9 





FL – Fludrocortisone phase; DOCP – DOCP and prednisolone phase 




Figure 9. Summary of ACTH results at the start and end of each trial phase 
Box and whisker plot of the ACTH concentrations at the start and end of each phase of the trial. 
The coloured box represents the interquartile range (Q3 to Q1; 50% of the data set) with the 
solid bar within the box representing the median result (Q2). The whiskers show the remaining 
data (the 5th to the 95th percentiles). Outliers are marked by a symbol. Outliers are observations 










3.4.7.2 Plasma renin activity  
Renin was measured at the start and end of the DOCP phase in all dogs and at the start 
and end of the fludrocortisone phase in all but one dog. During the DOCP phase, the 
renin concentrations stayed the same  (n=3) or decreased (n=27). During the 
fludrocortisone phase, it increased in 14 dogs, stayed the same in six dogs and 
decreased in nine dogs. The renin concentrations were undetectable in three dogs at the 
start of the DOCP phase (all group B) and in 19 dogs by the end of the DOCP phase 
(eight group A and 11 group B). Nine dogs had an undetectable renin at the start of the 
fludrocortisone phase (seven group A and two group B) and six had an undetectable 
concentration at the end of the fludrocortisone phase (four group A and two group B). 




















Figure 10. Summary of renin results at the start and end of each phase of the trial 
Box and whisker plot of the renin concentrations at the start and end of each phase of the trial. 
The coloured box represents the interquartile range (Q3 to Q1; 50% of the data set) with the 
solid bar within the box representing the median result (Q2). The whiskers show the remaining 
data (the 5th to the 95th percentiles). Outliers are marked by a symbol. Outliers are observations 













The renin concentrations were significantly lower at the end of the DOCP phase 
compared to the start (Wilcoxon Signed Rank test; P=0.000), but were not significantly 
different between the start and end of the fludrocortisone phase. They were also 
significantly lower at the end of the DOCP phase compared to the fludrocortisone phase 
(Wilcoxon Signed Rank test; P=0.000). Spearman correlation showed weak correlation 
(Figure 11) between the DOCP dose (mg/kg) and the renin concentration (P=0.010). 















Figure 11. Relationship between DOCP dose and renin at the end of the DOCP 
phase of the trial 
Scatterplot of the relationship between the DOCP dose and the renin results. Spearman 



























3.4.7.3 Blood pressure measurement 
The blood pressure was measured at each visit and was evaluated alongside heart rate.  
The systolic blood pressure (mmHg) was found to be significantly higher at the end of 
the DOCP phase (mean 161mmHg; SD 26.3) compared to the fludrocortisone phase 
(mean 147mmHg; SD 26.2) (Paired T test; P=0.006; Paired) and also at the start and the 
end of the DOCP phase (Paired T test; P=0.001). There was no significant difference 
between the systolic blood pressure at the start and end of the fludrocortisone phase. 
Using Spearman Correlation, there was no correlation between the systolic blood 
pressure at the end of each phase of the trial and the renin concentrations, and between 
the systolic blood pressure and either the DOCP dose or fludrocortisone dose (mg/kg) at 
the end of each trial phase. Table 12 and Figures 12 to 16 summarise the blood pressure 
results from different points on the trial.  
Assessing the cumulative scores of blood pressure from each trial visit during each 
phase of the trial (see section 2.7.3.3), the blood pressure decreased during the 
fludrocortisone phase and increased during the DOCP phase. The cumulative score at 
the end of the DOCP phase (24) was considerably higher than at the end of the 





Table 12. Summary of blood pressure at each visit on each phase of the trial 
This table shows the mean and standard deviation of the systolic blood pressure readings 
(mmHg) at each visit of the trial. The numbers in the pale blue boxes show the systolic blood 
pressure in mmHg. 
 
 A B C D E 
DOCP & Pred 
Phase 
 
Mean 154 148 141 147 148 
Standard 
Deviation  




Mean  143 154 147 159 161 
Standard 
Deviation  
18.8 25.7 25.7 22.3 26.2 
P Values  
Start and end of DOCP Phase 0.001* 
Start and end of Fludrocortisone Phase 0.136 













Figure 12. Blood pressures at differential time points during the trial 
Box and whisker plot of the blood pressure (systolic mmHg) at the start and end of each phase 
of the trial. The coloured box represents the interquartile range (Q3 to Q1; 50% of the data set) 
with the solid bar within the box representing the median result (Q2). The whiskers show the 













Figure 13. Comparison of mean systolic blood pressure on each phase of the trial 
Line graph of the mean systolic blood pressure (mmHg) for all dogs on each visit during each 









Figure 14. Relationship between systolic blood pressure and DOCP dose at the end 
of the DOCP Phase of the trial 
Scatterplot of the systolic blood pressure of all patients at the end of the DOCP Phase of the 


























Figure 15.  Relationship between systolic blood pressure and fludrocortisone dose 
at the end of the Fludrocortisone Phase of the trial 
Scatterplot of the systolic blood pressure of all patients at the end of the Fludrocortisone Phase 
















Figure 16. Relationship between systolic blood pressure and renin concentrations 
at the end of each phase of the trial 
Scatterplot of the systolic blood pressure of all patients at the end of each phase of the trial (x 






3.4.7.4 Haematology and biochemistry  
The only significant haematological finding was an increase in the neutrophil count at 
the end of the DOCP phase (mean 7.49x10^9/L; SD 3.1) compared to the 
fludrocortisone phase (mean 5.81x10^9/L; SD 2.31) (Paired T Test; P= 0.009). There 
were no significant differences between the lymphocyte and eosinophil counts at the 
end of each phase of the trial using a Wilcoxon Signed Rank test. On biochemistry, the 
urea was significantly lower (P=0.000; Wilcoxon Signed Rank test) at the end of the 
DOCP phase (median 5.3mmol/L; 2.9-11.7) compared to the end of the fludrocortisone 
phase (median 7.4mmol/L; 3.8-17.2). The creatinine was also significantly lower 
(Paired T test; P=0.001) at the end of the DOCP phase (mean 96µmol/L; 19.2) 
compared to the fludrocortisone phase (mean 109µmol/L 28.9). There was no 
significant difference in the albumin (Wilcoxon Signed Rank test), glucose (Wilcoxon 
Signed Rank test) or calcium (Paired T test) concentrations at the end of the DOCP 


















Table 13. Summary of haematology and biochemistry results 
The range and median of the main haematological and biochemical results. Although full 
haematology and biochemistry analytes were performed, these were considered to be the 
parameters directly associated with hypoadrenocorticism and its treatment. Therefore statistical 






Variable  Phase Minimum Maximum Median P value 
Neutrophils DOCP & Pred  0.48 14.23 7.51 0.009* 
Fludrocortisone  0.47 9.57 6.48 
Lymphocytes DOCP & Pred 0.29 1.99 1.12 0.119 
Fludrocortisone  0.25 4.29 1.05 
Eosinophils DOCP & Pred  0.00 0.74 0.18 0.581 
Fludrocortisone  0.00 1.22 0.18 
Urea DOCP & Pred  2.9 11.7 5.3 0.000* 
Fludrocortisone  3.8 17.2 7.4 
Creatinine DOCP & Pred  63 146 97 0.001* 
Fludrocortisone  65 192 107 
Albumin DOCP & Pred  28 44 33 0.209 
Fludrocortisone 25 41 33 
Glucose DOCP & Pred  0.0 9.1 5.0 0.509 
Fludrocortisone 4.0 6.1 4.9 
Calcium  DOCP & Pred  2.31 3.09 2.63 0.705 
Fludrocortisone  2.27 3.26 2.63 
RESULTS 
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3.4.8 Non-inferiority  
No dogs were hyperkalaemic at the end of the fludrocortisone or DOCP phases of the 
trial however three dogs were hyponatraemic at the end of the fludrocortisone phase. 
When using signs of glucocorticoid and mineralocorticoid under dose only, no dogs had 
clinical signs at the end of either phase of the trial.  Using these factors as indicators of 
success (lack of hyperkalaemia or hyponatraemia and no clinical signs of 
hypoadrenocorticism), DOCP and prednisolone were found to be non-inferior to 
fludrocortisone for the management of hypoadrenocorticism in dogs (Table 14).  This is 
as the success in the DOCP and prednisolone group was 100% and in the 
fludrocortisone was 90%. The lower bound 95% confidence interval of this difference 




















Table 14. Summary of Non-inferiority calculation 
This table shows how non-inferiority is calculated. It compares the primary outcome measures 
i.e. clinical signs and electrolytes. Only electrolyte results suggestive of under treatment (i.e. 
hyperkalaemia or hyponatraemia) were used. For DOCP and prednisolone to be non-inferior to 
fludrocortisone, the lower bound of the two-sided 95% confidence interval of the difference had 


























Na	 30	 90%	 100%	 -10%	 -1%	 Non-
inferior	
K	 30	 100%	 100%	 0%	 0	 Non-
inferior	
CS	overdose	 30	 17%	 17%	 0%	 0	 Non-
inferior	


















CS – Clinical signs  
CP – Control product; fludrocortisone phase 
IVP – Interventional product; DOCP and prednisolone phase 
CS overdose = increased thirst, increased urination, increased blood pressure, 
lethargy, coat changes, polyphagia 
CS underdose = vomiting, diarrhoea, lethargy 
(results of overdose and underdose were considered separately as only clinical signs 




4.1 Study Design 
4.1.1 General Study Design 
This study showed that DOCP and prednisolone were not inferior when compared to 
fludrocortisone acetate in the management of canine hypoadrenocorticism. Although 
several studies have shown the success of DOCP (Percorten®) (Kintzer and Peterson, 
1997b, Lynn and Feldman, 1991, Lynn et al., 1993, Melian and Peterson, 1996) in the 
management of this condition, the drug has never been directly compared to 
fludrocortisone acetate. The initial studies simply demonstrated efficacy with no 
comparison (Lynn and Feldman, 1991, Lynn et al., 1993). Later studies examined dogs 
with hypoadrenocorticism that had been transitioned from one drug to another when 
they have not been considered to be stable (Kintzer and Peterson, 1997b, Melian and 
Peterson, 1996). More recently, Zycortal® has been shown to be non-inferior to 
Percorten® however treatment with DOCP was not compared to fludrocortisone with 
prednisolone (Farr et al., 2020). 
In this study, a cross over design was used to compare DOCP and prednisolone to 
fludrocortisone acetate, with a cohort of patients receiving both drugs in a random order 
whilst being monitored in as uniformly as possible.  Randomisation into two groups was 
necessary to avoid sequence bias when comparing treatments. A single study site was 
selected to minimise the number of clinicians involved in the trial and to ensure 
consistency in dose adjustments which were unavoidably subjective in nature.  Regular 
meetings were arranged to discuss dosing decisions. This was important when 
considering the presence of clinical signs which was critical for assessment of 
glucocorticoid supplementation as no objective measure is readily available. In addition, 





A non-inferiority study design was selected over a superiority study design as 
hypoadrenocorticism is an uncommon condition and the case numbers required for a 
superiority study were considered to be unattainable. Non-inferiority was considered to 
be an adequate assessment of clinical control as studies have already shown 
fludrocortisone to provide adequate control of hypoadrenocorticism (Freise et al., 2013, 
Huitfeldt et al., 2011, Roberts et al., 2016). Superiority was therefore not required and 
instead it was simply necessary to determine that the licensed product was non-inferior 
to the unlicensed product. 
A cross-over design was chosen over a placebo-controlled trial as it was considered to 
be more practical. One way of performing a placebo-controlled trial would be to give 
every dog both an injection and tablets – one a placebo and one with an active 
ingredient. This was considered impractical, as clinicians were required to be aware 
which drug was being administered to assist with dose adjustments during the trial.   
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4.1.3 Outcome Measures 
The outcome measures were considered to be primary or secondary, where the primary 
measures were used to directly consider treatment success and secondary outcomes 
were retrospectively used as an adjunctive measure of drug efficacy. Primary outcome 
measures were electrolyte results and clinical signs. Electrolytes were chosen as they 
are a direct and rapid measure of mineralocorticoid supplementation which can be used 
to make adjustments to the DOCP dose. Clinical signs were considered to be the most 
practical and reliable measure of glucocorticoid overdose. Although endogenous ACTH 
might provide a reflection of the adequacy of glucocorticoid supplementation, this has 
not been formally demonstrated and, furthermore, it relies on measurement of a labile 
hormone at a specialist endocrine laboratory. Secondary outcome measures were not 
used to assess non-inferiorty however they were used to provide an overall assessment 
of clinical control of hypoadrenocorticism. Several secondary measures were used. The 
most useful of these were felt to be the measurement of endogenous ACTH and renin, 
which should reflect glucocorticoid and mineralocorticoid supplementation 
respectively. These results were reviewed retrospectively and were not used to assist 
with dose adjustments. Aldosterone is integral to the renin-angiotensin-aldosterone 
system which controls circulating volume and effectively, blood pressure. In addition, 
cortisol also exerts some effect on blood pressure. Therefore blood pressure was 
considered to be a useful secondary measure of control. Routine haematology and 
biochemistry were used as secondary measures to assess glucocorticoid and 
mineralocorticoid supplementation with a neutrophilia and monocytosis being 
associated with glucocorticoid overdose. A high urea and creatinine was thought to 
suggest mineralocorticoid underdose and hypoalbuminaemia or hypoglycaemia being 
associated with glucocorticoid underdose. 
4.1.4 Protocol Deviations 
Following the start of the trial, several amendments of the study protocol were required. 
These were to ensure completion of the trial with minimal bias and limitations.  
Initially the study protocol had stated that non-inferiority would be determined by 
treatment success at each visit during each phase of the trial (section 2.1). However it 
quickly became evident that patients were requiring several dose adjustments before 
being considered stable on DOCP and therefore, the treatment success at the end of each 
phase of the trial was considered for non-inferiority instead. 
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In addition, it became evident during the study that clinical signs of glucocorticoid 
overdose and hypokalaemia/hypernatraemia suggestive of mineralocorticoid overdose 
were common during the DOCP phase (section 3.3.6). These results suggested over 
supplementation of DOCP and prednisolone for management of hypoadrenocorticism 
and using the initial classification of non-inferiority, this treatment would have been 
found to be non-inferior to fludrocortisone. However, as the aim of the study was to 
ensure that patients were not being under supplemented with medication for 
management of hypoadrenocorticism, the non-inferiority criteria were adjusted to 
consider only patients with signs of underdosing. 
During the study period the branded preparation of fludrocortisone acetate (Florinef®, 
Bristol) became unavailable. Therefore a generic fludrocortisone tablet formulation 
(Aspen Pharmaceuticals) was used instead. This formulation was more expensive and 
only limited stocks were available (even for human use). Therefore the protocol was re-
appraised to reduce the use of fludrocortisone. It was noted that the washout period at 
the end of the fludrocortisone phase was not needed and so this was stopped. As a result 
only one dog had a washout period when treatment had been started with 
fludrocortisone. This meant the total trial period varied between the two groups of 
patients but this was not considered to affect the study results. The generic tablets did 
not require storing at refrigerated temperatures however their pharmacokinetics were 
assumed to be the same as Florinef®. This is a potential limitation of the study.   
4.1.5 Visits 
Visit compliance throughout the study was good (section 3.3.3, Table 8 and Figure 2). 
This was most likely due to careful client education prior to patient enrolment, to ensure 
willingness to comply.  Some visits were slightly early or late however efforts were 
made to ensure the visits were within 3 days of their scheduled date to allow reliable 
comparison between patients. Due to unavoidable issues such as owner illness or work 
commitments, some visits were outwith this window. 
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The number of unscheduled visits was far greater than expected. The majority of these 
visits were during the DOCP phase of the trial. The reasons for this were mainly due to 
the starting dose of DOCP being too high in most patients and numerous dose 
reductions being required. This meant that 10 day checks were required for many 
patients during the DOCP phase of the trial (section 3.3.4). The trial protocol has 
accounted for ten day visits (B visits) ten days after the A visit. If the starting dose of 
DOCP was lower, the majority of these visits would not have been required. In addition, 
there were a significant number of unscheduled visits required as DOCP injections were 
having a prolonged duration of action (most likely due to the high starting dose), or less 
commonly, a short duration of action. As discussed, patients 13 had several unscheduled 
visits due to suspected adverse effects of DOCP (section 3.2).  
4.2 Study Population 
4.2.1 Inclusion and Exclusion Criteria 
Three patients were excluded from the trial: one was not diagnosed with an ACTH 
stimulation test, one was diagnosed with hypothyroidism at enrolment and one died of a 
ruptured haemangiosarcoma. 
There were two patients who did not meet the initial inclusion/exclusion criteria but that 
were included in the trial. Patient 29 was included in the trial despite being on topical 
steroid eye drops. The dose of this medication was unchanged during the trial period 
and the route of administration of this drug was topical rather than systemic. This 
patient had also been on eye drops containing a glucocorticoid for 13 days before its 
ACTH stimulation test. Although adrenocortical suppression has been suggested with 
ophthalmic steroid preparations (Roberts et al., 1984, Zenoble and Kemppainen, 1987), 
it is more widely accepted to be associated with otic steroid preparations (Ghubash et 
al., 2004). As topical steroid preparations have been shown to reduce the responsiveness 
of cortisol to ACTH stimulation rather than causing clinical adrenocortical failure (such 
as electrolyte derangements and gastrointestinal signs), this patient was not excluded 
from this study. The patient did have electrolyte derangements (hyperkalaemia and 
hyponatraemia) at the time of diagnosis. In addition, the patient responded favourably to 
mineralocorticoid and glucocorticoid supplementation and had a signalment which was 
consistent with primary spontaneous hypoadrenocorticism.  Considering these factors, 
this patient was included in the trial.  
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One patient (Patient 15) had a pre-existing diagnosis of a recurrent malassezia otitis 
externa. This had resolved by the time of enrolment however it had been treated with 
oral ketoconazole and amoxicillin clavulanic-acid (Synulox, Zoetis). The patient had 
become unwell eight days following the introduction of ketoconazole, at which point 
this drug had been discontinued and ACTH stimulation test was performed to 
investigate hypoadrenocorticism as a cause of illness.  Although ketoconazole is used to 
treat hyperadrenocorticism and causes inhibition of multiple cytochrome P450 enzymes 
including those involved in steroidogenesis (Sanders et al., 2018), it has not been 
reported to show results of ACTH stimulation tests which mimic that of primary 
hypoadrenocorticism. Therefore, although ketoconazole can result in a reduced response 
to an ACTH stimulation test, it is not classically considered to cause a complete lack of 
stimulation as is often seen with hypoadrenocorticism (Lathan and Thompson, 2018) 
and this patient was not excluded from this study. 
4.2.2 Patient Illness During The Study Period 
Three patients required antibiosis for management of pyoderma and one patient for a 
urinary tract infection. The conditions and the antibiotics used were not considered to 
interfere with the trial protocol. These conditions were not considered to be an adverse 
reaction to the trial drugs. However, it is possible that chronic steroid therapy, 
particularly if at doses higher than required for glucocorticoid replacement, could lead 
to an increased risk of development of infections due to suppression of the immune 
system.  
One patient was prescribed clindamycin by its primary care veterinarian to manage an 
episode of colitis. Although this drug was not thought to interfere with the trial, it is 
possible that the colitis could have been considered a sign of hypoadrenocorticism. As 
this diarrhoea responded to antibiotic therapy and as there were no other signs fitting 
with unstable hypoadrenocorticism, it was suspected to be an unrelated event.  
Several other drugs including analgesics and urinary incontinence drugs were prescribed 
during the trial however these were not considered to interfere with the trial protocol. 
Two patients did require management for suspected trial drug related events.  
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Patient 13 required recurrent hospitalization and unscheduled visits. These ranged from 
5 to 16 days post DOCP injection and two unscheduled visits were required each time. 
Supportive treatment was required for signs of nausea, lethargy and weakness. During 
these episodes this patient was hypokalaemic and hypertensive. In addition, each 
episode occurred at around day 10 following DOCP injections. Therefore, these events 
were suspected to be due to mineralocorticoid over-supplementation. Spironolactone 
was given as an aldosterone antagonist to resolve these effects of mineralocorticoid 
overdose. On one visit, buprenorphine was also prescribed as the patient had marked 
abdominal discomfort. This patient was suspected to have pancreatitis as a point of care 
analyser for canine specific pancreatic lipase (SNAP cPLTM, IDEXX) was abnormal and 
there were also ultrasonographic changes supportive of this condition. Although the 
onset of pancreatitis could have been unrelated to the trial, it is possible that this was a 
side effect of the DOCP given the condition occurred when the drug was at its highest 
systemic concentration. This patient did not require any unscheduled visits during the 
fludrocortisone phase of the trial, nor did it show any abnormal clinical signs during this 
phase.  
Patient 22 received maropitant 9 days after its third dose of DOCP due to vomiting and 
the onset of signs of nausea (lip smacking and inappetence). Only one dose of 
buprenorphine was required and it is likely that this was an incidental sign. However 
given this occurred 9 days after DOCP injection, at the time when the drug is suspected 
to be at its highest concentration, it has to be considered that this event could have been 
drug related.  More specifically, as another patient suffered recurrent pancreatitis as 
discussed, it is possible that this was the cause of the vomiting. Further investigations 
were not performed given the quick resolution of the signs. 
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There seems to be no theoretical link between pancreatitis and over supplementation of 
mineralocorticoid. Patients with naturally occurring mineralocorticoid excess (such as 
feline primary hyperaldosteronism in veterinary medicine) do not commonly develop 
pancreatitis (Andrew et al., 2005, Djajadiningrat-Laanen et al., 2011). Glucocorticoid 
excess has been speculated to be associated with pancreatitis and hyperadrenocorticism 
is thought to be a risk factor for the development of acute pancreatitis (Hess et al., 
1999). Other dogs with hyperadenocorticism show increased Spec cPLI without clinical 
signs of pancreatitis (Mawby et al., 2014). However, although exogenous 
glucocorticoids are expected to increase the release of pancreatic enzymes from the 
pancreas, clinical pancreatitis has not been demonstrated experimentally (Parent, 1982). 
Several studies have looked at the development of pancreatitis with exogenous 
glucocorticoid supplementation and have not shown the same link to pancreatitis as 
with hyperadrenocorticism (Barzilai et al., 1986, Fittschen and Bellamy, 1984). The 
mechanism of the potential increased incidence of pancreatitis with excessive 
glucocorticoid concentrations is unknown and it is possible that a similar mechanism is 
responsible for dogs developing pancreatitis when being treated with DOCP and 
prednisolone. As the suspected episodes of pancreatitis developed at the point of 
maximum mineralocorticoid concentrations, it seems more likely that it is related to 
mineralocorticoid overdose. This should be considered when treating patients with 
DOCP and further studies are required to investigate the pathological mechanism 
involved.  
4.3 Study Results 
4.3.1 Study Population 
There were 16 dogs in Group A and 14 dogs in Group B.  The discrepancy between 
group numbers was due to 33 doings being enrolled and three being excluded; two dogs 
excluded were in group B and only one was group A.  The general study population was 
representative of dogs with hypoadrenocorticism. The weight of the two groups was 
statistically significantly different however this was not suspected to be of clinical 
relevance as all doses were calculated in mg/kg. The gender distribution was also 
different between the groups but as no studies have shown any differences in disease 
severity or response to treatment between gender or neuter status, this was also not 
considered to be significant. Therefore, the two groups were combined for analysis and 
each dog acted as its own control given the cross-over design.  
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4.3.2 Indicators of Disease Control (Outcome Measures)  
4.3.2.1 Electrolytes 
The primary outcome measure for assessing mineralocorticoid control was the sodium 
and potassium concentrations. Either hypokalaemia or hypernatraemia was considered 
to indicate over supplementation of mineralocorticoid and conversely, hyperkalaemia 
and hyponatraemia indicated under supplementation.  Although concurrent illness or 
laboratory analyser error could have both led to electrolyte abnormalities, the 
assumption was made that any electrolyte derangements were related to 
mineralocorticoid supplementation. This was as there was no method of controlling this 
and patients did not show clinical signs to suggest otherwise.  
Although dogs enrolled on the trial were considered to be stable on fludrocortisone 
treatment, the sodium concentrations were below the lower reference range 5 times 
during the fludrocortisone phase of the trial. This would suggest under supplementation 
of mineralocorticoid. It is however important to note that the lowest sodium result of the 
trial was at the E visit of the fludrocortisone phase of the trial and that this result was 
considered to be spurious (111.8 mmol/L) because such a marked hyponatraemia would 
be expected to be associated with clinical signs. In addition, the sodium was measured 
on a point-of-care machine from the same sample and was found to be 147 mmol/L.  
One patient had low potassium whilst on the fludrocortisone phase of the trial. No 
hypokalaemia had been noted previously and it resolved on subsequent visits without a 
fludrocortisone dose reduction. Therefore, this result was also considered to be 
spurious.   
In contrast, the potassium concentrations were low on 12 occasions during the DOCP 
phase trial. This is suggestive of mineralocorticoid excess and given this finding was 
not seen on the fludrocortisone phase, it would suggest overdosing of DOCP. No 
patients had hyperkalaemia or hyponatraemia to suggest under supplementation of 
mineralocorticoid during the DOCP phase of the trial.  
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Comparing the two phases of the trial, both the sodium and potassium concentrations at 
the end of each phase of the trial were significantly different (section 3.3.6.1). During 
the DOCP phase, the potassium concentrations generally decreased and the sodium 
concentrations increased. The opposite was true for fludrocortisone, suggesting 
fludrocortisone was more commonly associated with under supplementation of 
mineralocorticoid and DOCP with over supplementation. Patients were considered to be 
stable on fludrocortisone at the time of enrolment and therefore this was an unexpected 
finding of the trial. 
The DOCP dose (mg/kg) showed weak positive correlation with the potassium 
concentrations at the end of the DOCP phase of the trial. This finding was not 
considered to be significant as it was clearly observed that reducing DOCP dose 
increased the potassium levels during the study. As this correlation was between the 
DOCP dose at the end of the DOCP phase and the potassium levels, it may not be 
representative of the relationship throughout the trial.  
Using the target range of 27-32 for the sodium:potassium ratio, many dogs were 
perceived to be well controlled clinically but with high sodium:potassium ratios. 
Therefore this range provides an inaccurate and overly sensitive method for monitoring 
hypoadrenocorticism.  It is concluded that 32 seems to be too low to be suitable for the 
upper reference range for the sodium:potassium ratio when monitoring dogs on DOCP, 
as this would have incorrectly led to dose reductions in dogs with individual electrolytes 
within the normal reference range. Increasing the upper reference range to 42 would be 
more clinically appropriate for detecting over treatment with DOCP.  Conversely, using 
the sodium:potassium ratio missed dogs with hyponatraemia that were being under 
supplemented with fludrocortisone.  Therefore, a more appropriate approach may be to 
consider each electrolyte result individually, with respect to its own reference range, 






4.3.2.2 Clinical Signs  
Despite the electrolyte concentrations being suggestive of under supplementation of 
mineralocorticoid in dogs during the fludrocortisone phase of the trial, no dogs showed 
clinical signs of mineralocorticoid or glucocorticoid deficiency during this phase. One 
dog (Patient 13) did show signs which could be consistent with mineralocorticoid or 
glucocorticoid deficiency during the DOCP phase of the trial, however given concurrent 
hypokalaemia and hypertension and considering the timing of this episodes, these signs 
were instead suspected to be due to mineralocorticoid over supplementation. 
During the fludrocortisone phase of the trial, the number of dogs showing clinical signs 
of glucocorticoid excess decreased. This may have been as group A dogs were on 
prednisolone with DOCP prior to starting the fludrocortisone phase. This was in 
contrast to the DOCP phase where the clinical signs of glucocorticoid excess increased 
substantially. During the DOCP phase, prednisolone was given concurrently with 
DOCP. Most dogs required a dose reduction of both drugs and overall it seems that both 
glucocorticoids and mineralocorticoids were being over-supplemented in many dogs 
during this phase of the trial. 
It was very difficult to use clinical signs of mineralocorticoid excess such as polyuria, 
polyphagia and weakness as markers of control as they were non-specific signs and 
could be consistent with either mineralocorticoid or glucocorticoid deficiency or excess.  
Day 10 was thought to be the most fitting time for signs of mineralocorticoid excess to 
manifest as this is when DOCP is thought to be at its highest systemic concentration. 
Generally though, blood pressure and weakness were assessed to give a more specific 
marker of mineralocorticoid control. Looking at blood pressure, the systolic blood 
pressure was significantly higher during the DOCP phase compared to the 
fludrocortisone phase of the trial. This again fits with the suggestion that DOCP is a 
very efficacious drug and the starting dose is too high for the majority of patients. 
4.3.2.3 ACTH concentrations 
ACTH is produced from the pituitary gland and increases cortisol (and to a lesser extent 
aldosterone) production from the adrenal gland, however dog to dog variation may 
exist. Negative feedback exerted on the pituitary gland by cortisol, leads to reduction of 
ACTH production. Therefore, if endogenous or exogenous glucocorticoid 
concentrations are high, ACTH production can be suppressed. It was hypothesised that 
endogenous ACTH might be a useful marker of glucocorticoid control, with ACTH 
being high with glucocorticoid deficiency and low with glucocorticoid excess. 
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ACTH concentrations were reduced in over two thirds of dogs in the DOCP phase of 
the trial.  The concentrations were actually undetectable in half of the dogs during the 
DOCP phase of the trial. This is consistent with the clinical signs of glucocorticoid 
overdose and suggests that the prednisolone doses used were too high. There was 
however no correlation between prednisolone dose (mg/kg) and the ACTH 
concentrations. This fits with observations that the glucocorticoid supplementation 
required is very variable between individual patients.  
4.3.2.4 Plasma renin activity  
Renin is produced from the juxtaglomerular apparatus of the kidneys in response to low 
circulating blood volume and high sodium concentrations. It leads to the activation of 
the RAAS system (including aldosterone release from the adrenal gland) and 
subsequently to water reabsorption from the kidneys. Therefore, excessive aldosterone 
concentrations would be expected to cause suppression of plasma renin activity and 
mineralocorticoid deficiency would cause an increase in plasma renin activity. It was 
hypothesised that renin concentrations may be a useful marker for mineralocorticoid 
control. 
During the DOCP phase, the renin concentrations decreased in the majority of dogs. In 
addition, the renin concentrations were almost undetectable in almost two thirds of the 
patients during the DOCP phase of the trial. The renin concentrations were significantly 
lower at the end of the DOCP phase of the trial compared to the fludrocortisone phase. 
There was significant correlation between the DOCP dose (mg/kg) and the renin 
concentrations. This suggests the DOCP has potent mineralocorticoid actions and 
particularly in patients where the renin activity was completely undetectable, perhaps 
the DOCP dose was too high. It is possible that dogs with undetectable renin 
concentrations would have had normalization of plasma renin activity with further dose 
reductions of DOCP, however follow-up samples were not obtained after conclusion of 
the trial. 
There was no appreciable relationship between the fludrocortisone dose (mg/kg) and the 
renin concentrations. In several patients being treated with fludrocortisone the renin 
increased and was above the upper reference limit. As discussed, these patients showed 
no signs of mineralocorticoid deficiency. This raises concerns that patients being treated 
with fludrocortisone could be being under-supplemented with mineralocorticoid, despite 
showing no clinical signs of hypoadrenocorticism.  
 
109 
4.3.2.5 Blood pressure measurement 
Blood pressure was used as an indirect marker of mineralocorticoid control, with 
normotension being consistent with good control, hypotension being consistent with 
under control and hypertension being consistent with over control. The systolic blood 
pressure (mmHg) was found to be significantly higher at the end of the DOCP phase 
compared to the fludrocortisone phase and also at the start and the end of the DOCP 
phase. This is another factor which is supportive of DOCP efficacy and effective 
mineralocorticoid supplementation. Despite this finding, there was no relationship 
found between the DOCP dose and the blood pressure or the renin concentrations and 
the blood pressure. Although the renin concentrations were high in several patients on 
the fludrocortisone phase of the trial, no patients were hypotensive.  
4.3.2.6 Haematology and biochemistry  
The only significant haematological finding was an increase in the neutrophil count at 
the end of the DOCP phase compared to the fludrocortisone phase. This is most likely 
due to prednisolone therapy during this phase of the trial, with glucocorticoids 
(endogenous and exogenous) leading to a neutrophilia or a “stress leukogram”. This 
could again be suggestive of glucocorticoid over supplementation during the DOCP 
phase of the trial. 
On biochemistry, the urea and creatinine concentrations were both significantly lower at 
the end of the DOCP phase compared to end of the fludrocortisone phase. Although 
prednisolone therapy can cause polyuria with subsequent decreases in urea, this could 
also be consistent with mineralocorticoid excess. These results suggest adequate 
management of hypoadrenocorticism as poorly managed patients trend towards 
azotaemia. Otherwise there were no statistical differences on biochemistry between the 
two groups.  
4.3.2.7 Overall Interpretation of Outcome Measures 
These results would suggest that during the DOCP phase of the trial, both 
mineralocorticoids and glucocorticoids were over supplemented and further dose 
reductions should have been considered. Given the trial protocol, further drug 
adjustments could not be achieved during the trial. However following completion of 
this trial, several dogs required and benefited from further dose reductions. Despite this, 
all dogs were perceived to be clinically well controlled at the end of the trial.  
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In contrast, there was suggestion that dogs treated with fludrocortisone were 
undertreated with mineralocorticoids and glucocorticoids, based on endogenous ACTH 
and plasma renin activity result.  
4.3.2.8 Statistical analysis 
Although numerous statistical tests including Paired T tests, Wilcoxon Signed Rank 
tests and Spearman/Pearson correlation were performed (section 2.7), each individual 
variable was not tested more than twice, or three time in the case of blood pressure 
analysis. Despite this, Bonferroni adjustments were made to all P values to assess how 
this would affect the study results. Of the 33 statistical tests with P value corrections, 
the significance was affected on only one occasion. In this instance, the number of 
patients with hypertension and weakness was significantly different at the end of the 
fludrocortisone phase compared to the end of the DOCP phase, with a P value of 0.035 
when using a cut off of P= 0.05. However, with Bonferroni correction the P value was 
adjusted to 0.025 which meant the P value of 0.035 lost significance. 
The Bonferroni-Holm method is a less conservative method of adjusting the P value to 
reduce the risk of getting type I errors (ie finding significance due to chance given the 
number of statistical tests performed).  It is possible that this method of P value 
adjustment could have led to a greater proportion of results losing significance, however 
this method was not performed. This was for several reasons such as: avoidance of a 
type I error was not considered more important than avoidance of a type II error; 
although numerous statistical tests were performed, they were not performed 
repetitively on the same result; the study was prospective and the statistical tests used 
were pre-determined and finally, these adjustments in P values would have effected 
only the secondary and not the primary outcome measures and therefore would not have 
affected the non-inferiority calculation (Armstrong, 2014).  
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4.3.3 Drug Doses and Dose Adjustments 
Overall, there were very few fludrocortisone dose adjustments required as patients were 
considered stable at the point of entry.  Dose reductions were required due to clinical 
signs of glucocorticoid overdose. There were no apparent clinical signs or biochemical 
changes consistent with mineralocorticoid overdose or under dose during the 
fludrocortisone phase. Dogs enrolled on the trial were perceived to be clinically stable 
on fludrocortisone and therefore it is not surprising that dose adjustments were 
uncommon. As fludrocortisone has both mineralocorticoid and glucocorticoid activity, 
it can be challenging to find the correct dose for both glucocorticoids and 
mineralocorticoids concurrently, as dogs require different proportions of each steroid.  
The final median dose of fludrocortisone (0.012mg/kg twice daily) was similar to that 
recommended by the BSAVA Small Animal Formulary (Ramsey, 2017). 
Conversely, DOCP was a new treatment for all dogs on the trial. Although DOCP has 
been used in the management of canine hypoadrenocorticism previously, Zycortal® had 
not been extensively used before. Therefore, starting doses were extrapolated from 
studies using a different drug formulation (Percorten®) and historical efficacy studies 
(Farr et al., 2020). It is therefore understandable that numerous dose adjustments were 
required throughout the trial period. Most commonly, dose reductions in DOCP were 
required. Numerous patients showed electrolyte derangements (most commonly 
hypokalaemia) and one patient (Patient 13) may have suffered recurrent illness due to 
the effect of mineralocorticoid excess.  
Although a much lower starting dose seems advisable (median dose range at the end of 
the DOCP phase 1.74mg/kg every 28 days), it is important to note that two dogs 
required dosing every 25 days due to apparent reduced length of action of DOCP and 
one dog required dose increases to 2.6mg/kg every 28 days. As the clinical signs of 
under dosing of mineralocorticoid supplementation can be more dangerous and 
debilitating than over dosing, it seems sensible to start with a slightly higher dose with 
subsequent dose reductions than to start with a lower dose and require dose increases. 
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Over two thirds of dogs required prednisolone dose reductions during the DOCP phase 
of the trial. Only one dog was supplemented with prednisolone during any point of the 
fludrocortisone phase of the trial and this drug was discontinued during this phase. Dose 
reductions were advised due to the presence of a combination of polyuria, polydipsia, 
panting, polyphagia and coat changes. The former three of these signs can also be seen 
with mineralocorticoid excess and therefore this made interpretation of prednisolone 
dosage difficult.  
Although the starting dose of prednisolone generally seemed too high, the final dose 
varied dramatically between individuals. There appeared to be no relationship between 
weight and prednisolone dose. One 56kg patient required only 1mg daily whereas a 
20kg dog required 10mg of prednisolone daily. Therefore, it is important that thorough 
histories are obtained to ensure optimal prednisolone dosing and to avoid over or under 
supplementation of glucocorticoid. Both under and overdosing of prednisolone can have 
significant detrimental effects on patients. 
The median dose of prednisolone at the end of the DOCP phase of the trial was 
0.13mg/kg once a day (range 0.02-0.35). Although more commonly employed when 
giving larger doses of prednisolone, metabolic weight (e.g. mg/m2 dosing) can be used 
as an alternative to mg/kg doses. This is thought to be more accurate and tends to lead 
to smaller mg/kg doses being used in larger dogs (Nam et al., 2017). In this study we 
did not evaluate the relationship between mg/m2 dosing and different variables or look 
for significance of doses of prednisolone compared to weight when using mg/m2 dosing 
(or other measures of metabolic weight).  There have been no studies looking at mg/m2 
dosing with DOCP however this could be a more reliable way to dose dogs with DOCP 
given the vast range in doses required.  
4.3.4 Overall Assessment of Treatment Response 
This study showed that DOCP and prednisolone were non-inferior to fludrocortisone for 
the treatment of hypoadrenocorticism.  This conclusion is based on the fact that no 
patients were hyponatraemic, hyperkalaemic or had clinical signs of 
hypoadrenocorticism at the end of the DOCP phase of the trial (and was confirmed 
using the non-inferiority calculation).  
Therefore, this treatment could not be inferior to fludrocortisone, regardless of the 
results during the fludrocortisone phase. Three patients were hyponatraemic at the end 
of the fludrocortisone phase of the trial and this was indicative of an inferior 
performance of this drug compared to DOCP.  
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Two protocol amendments were required to reach this conclusion. This was as first of 
all, the starting dose of DOCP appeared to be too high with some patients requiring 
significant dose reductions. If adhering to the original study protocol (section 2.1) 
which stated that electrolytes must be within the normal reference range to consider 
“treatment success”, then numerous treatments would have been considered 
unsuccessful due to over treatment. However clinically, this was not considered to be a 
treatment failure as with subsequent dose reductions following conclusion of the trial 
period, the patients with electrolytes out with the normal reference range at the end of 
the DOCP phase were later considered to be very well controlled. In addition, if 
considering the clinical signs and electrolytes at each visit, DOCP would have likely 
seemed inferior to fludrocortisone. The trial period was three months to allow for dose 
adjustments and stabilization on a new medication and therefore it was decided that the 
clinical signs and electrolyte results at the end of each phase of the trial was a more 
accurate reflection of control of disease. 
At no points during the DOCP phase of the trial did patients show hyperkalaemia or 
hyponatraemia, which would fit with poor mineralocorticoid control. Although one 
patient was hyperkalaemic on the A visit of this phase, this would have been before 
DOCP was given and therefore reflective of mineralocorticoid supplementation from 
fludrocortisone. In addition, five dogs were hyponatraemic during the fludrocortisone 
phase of the trial, suggesting that mineralocorticoid supplementation was more likely to 
be inadequate during this treatment phase.  
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4.3.5 Follow Up 
After conclusion of the trial, the majority of dogs returned to our hospital until 
considered stable on DOCP. All dogs were eventually discharged from our hospital with 
no signs of steroid deficiency or excess and with electrolytes within the normal 
reference range. Owners, who had been filling out quality of life questionnaires at each 
visit were asked which treatment they felt their pet was happiest on and they all 
answered DOCP with prednisolone. Initially, the plan had been to allow owners to 
choose which treatment they would like their dog to continue on. However, as Florinef® 
became unavailable during the study period and as generic fludrocortisone was very 
expensive, the licensed form of DOCP (Zycortal®) was released to provide an 
affordable treatment option for hypoadrenocorticism in dogs. As Zycortal® is a licensed 
treatment, fludrocortisone could not be used without using the cascade and therefore 
owners were no longer given this choice. Regardless of this technicality, most owners 
were keen to continue treatment with DOCP. 
Fludrocortisone has both mineralocorticoid and glucocorticoid effects and therefore 
each type of steroid could not be individually titrated to each patient’s specific 
requirements. Subjectively, patients seemed to be mineralocorticoid deficient on 
fludrocortisone more than glucocorticoid deficient.  This is suggested by hyponatraemia 
and a generally increased plasma renin activity compared to the DOCP phase. It is 
therefore the author’s view that the glucocorticoid content of fludrocortisone is too high 
in proportion to the mineralocorticoid content for the majority of patients, leading to 
side effects of glucocorticoid excess such as polyuria, polydipsia, polyphagia and hair 
loss. These clinical signs can be distressing to owners and may lead to dose reductions 
in fludrocortisone, reducing glucocorticoid supplementation to a more appropriate 
concentration but at the expense of causing subclinical mineralocorticoid deficiency. 
Both the mineralocorticoid and glucocorticoid doses varied between patients with no 
relationship to weight. Therefore, DOCP and prednisolone appear to be a more 
appropriate treatment which allow individual mineralocorticoid and glucocorticoid dose 
adjustments. DOCP generally seems more potent, with several dose adjustments being 




4.4.1 Case Selection 
Given the nature of the trial, primary care veterinary practices were approached to 
provide potential cases to enrol. This ensured patients were representative of a general 
population of dogs with hypoadrenocorticism however it perhaps selected dogs with 
owners who were extremely committed to their pets which may not have been 
representative of a general population of owners.  In addition, patients were excluded 
for behavioural reasons and many dogs with hypoadrenocorticism could not be included 
as their owners could not comply with the intensive study protocol. As the study 
provided 6 months of free treatment, this also could have impacted on case selection 
and enrolment. Another limitation was that patients had to be stable on treatment with 
fludrocortisone and that no newly diagnosed patients were included. This prevented 
inclusion of dogs which may have benefited from treatment with DOCP as dogs can 
take a long time to stabilise on fludrocortisone therapy (Roberts et al., 2016). This also 
meant comparisons were made between patients stable on one treatment 
(fludrocortisone) and unstable on another (DOCP with prednisolone) at the start of each 
trial phase. 
4.4.2 Fludrocortisone Availability 
Florinef® (fludrocortisone acetate) became unavailable during the study period. 
Although this drug was considered to be pharmacologically identical to the generic 
formulation, this introduced a protocol deviation. The two drug formulations had 
different storage requirements which impacted on consistency within the trial. In 
addition, the generic drug was significantly more expensive which had a great impact 
on the trial budget. This meant that the washout period needed to be withdrawn 
following the fludrocortisone phase and prevented the two streams of the trial being 
identical. One patient did still have a washout period during the fludrocortisone phase of 
the trial and this meant that all dogs within the fludrocortisone phase did not receive 
identical treatment.  
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4.4.3 Clinical Signs Assessment  
Clinical signs were considered a primary outcome measure and were critical in deciding 
upon glucocorticoid control in particular as no readily available blood test provided an 
alternative marker of control. Therefore, clinical signs were very important in our 
interpretation of treatment success. However, assessment of clinical signs is a very 
subjective tool and varies between owners both within and between households. 
Interpretation of clinical signs is also likely to vary between clinicians. Questionnaires 
were used to make assessment slightly more objective however these questionnaires 
were not validated for this use and instead were formulated purely for trial purposes. 
Validation of the questionnaire used could have improved assessment of clinical signs 
and would have allowed statistical analysis of clinical signs between groups. Instead, 
descriptive analysis was used as the assessment had been subjective.  
Another limitation with assessment of clinical signs was the overlap between clinical 
signs of glucocorticoid and mineralocorticoid excess and deficiency. For example, 
polyuria and polydipsia could be suggestive of glucocorticoid or mineralocorticoid 
excess. Lethargy could be fitting with glucocorticoid excess or deficiency or 
mineralocorticoid excess or deficiency. Gastrointestinal signs could fit with 
mineralocorticoid excess or deficiency. Therefore, thorough histories, biochemical 
results and timing were used to help assist in interpretation of these signs however it 
was impossible to define what was causing each sign. Therefore, errors could have been 
made whilst considering the presence of clinical signs.  
4.4.4 The Study Protocol 
Several protocol deviations and amendments were required. Other than the 
unavailability of fludrocortisone, none of these were thought to have a direct impact on 
the results. One patient was included who was on a topical steroid preparation during 




During the trial, although all blood samples were submitted to a reference laboratory, 
decisions regarding mineralocorticoid control and dosing adjustments needed to be 
made at the time of the visit. Therefore, bloods were also run on a point of care analyser 
(section 2.5.2.2).  It is a limitation of this study that the electrolyte results discussed 
were not the exact results used to consider dose adjustments. Since there are inherent 
differences between analyser methodologies, it is important that the same analyser is 
used for dose (Fowlie et al., 2020). As the aim of this trial was to assess non-inferiority 
and not to review the intricacies of managing patients with hypoadrenocorticism with 
DOCP and prednisolone, accuracy (of the reference laboratory) rather than practicality 
(of the point of case analyser) was prioritised.  
Although DOCP and prednisolone were non-inferior to fludrocortisone, the overall 
performance of this treatment method was suboptimal due to the over-treatment of 
many patients. Patients only remained on each phase of the trial for three months and 
this time was not long enough to reach the optimum dosing regimen for all patients. If 
there had been a longer period of time on each phase of the trial, the performance of 
DOCP, and likewise the under supplementation from fludrocortisone, may have become 
more apparent. The length of the DOCP phase was a major limitation of this trial as it 
did not allow for complete stabilisation of all patients. 
4.5 Clinical Implications 
As Zycortal® is a licensed preparation of DOCP in Europe and fludrocortisone is not 
licensed, this is the recommended treatment for canine hypoadrenocorticism in Europe. 
Fludrocortisone can be used under the cascade if required. It should however be noted 
that the results of this study suggest subclinical mineralocorticoid deficiency in some 
patients using fludrocortisone as indicated by hyponatraemic episodes and increase in 
plasma renin activity.  
Although DOCP tended toward over supplementation of mineralocorticoids, all patients 
were considered to be clinically well controlled, particularly after a longer period of 
dose adjustments. The median dose of DOCP at the end of the DOCP phase was 
1.74mg/kg every 28 days and this would be expected to be lower if patient follow up 
had been longer. As some patients did require a dose increase in DOCP, it is 
recommended that the starting dose of DOCP is not too conservative and 1.6mg/kg 
every 28 day seems appropriate.  
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When assessing the dose of DOCP, it is recommended that sodium and potassium are 
reviewed independently rather than using sodium: potassium ratios. This is as the results 
show that sodium:potassium ratios can miss patients with one electrolyte outwith the 
normal reference range. In addition, the upper limit of the sodium:potassium reference 
range of 32 is unrealistic for patients on DOCP treatment and could lead to excessive 
dose adjustments. Hypokalaemia or hypernatraemia at any point following DOCP 
dosing should lead to a dose reduction and conversely, hyperkalaemia or hyponatraemia 
should result in a dose increase of the drug.  
No definitive drug side effects have been found during this study, although one patient 
was thought to develop pancreatitis at a time when the drug was at its highest systemic 
concentration. This condition was transient and recurrent episodes of the condition 
resolved with dose decreases in DOCP. Therefore, although overdosing of DOCP could 
potentially cause side effects such as weakness, lethargy and pancreatitis, the drug is 
considered to be safe and well tolerated. Suspected drug overdoses can be managed with 
spironolactone, an aldosterone receptor blocker. 
In the future, further studies investigating the volume of DOCP dose adjustments based 
on in-house electrolyte measurements at day 10 and day 28 are required. In addition 
patients require longer follow up to first of all find their individual optimum dosing 
regime and second of all, to monitor the long-term stability of patients. Studies showing 
long term control with Zycortal® and prednisolone and whether glucocorticoid or 
mineralocorticoid requirements change with time are lacking. In addition, dose 
requirements are highly variable between patients and other methods of dosing such as 
mg/m2 could be considered to assist in determining more universally appropriate 
starting doses for both medications. It would also be interesting to look at the use of 
other steroid preparations, particularly long acting steroid injections such as 
methylprednisolone (Depo-medrone®) which could allow for monthly injections of two 
forms of steroid. 
In humans, adrenal autotransplantation has been attempted in the 1960’s with poor 
success (Hardy et al., 1985). More recently, allotransplantation and stem cell biology 
have shown more promise for regaining functional adrenal tissue in human patients 
(Vouillarmet et al., 2013, Dubernard et al., 1995). Although numerous animal models 
have been considered (Thomas et al., 1997), these procedures are still in their infancy 




DOCP and prednisolone have been found to be non-inferior to fludrocortisone in the 
management of canine hypoadrenocorticism. This is the first study to directly compare 
both treatment methods using a randomised cross-over trial rather than switching from 
one drug to another following treatment failure. In conclusion, DOCP and prednisolone 
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